```
=> fil reg
FILE 'REGISTRY' ENTERED AT 16:36:17 ON 21 SEP 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   20 SEP 2000  HIGHEST RN 289881-52-3
DICTIONARY FILE UPDATES:  20 SEP 2000  HIGHEST RN 289881-52-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
for details.

=> d ide can tot

L78  ANSWER 1 OF 11  REGISTRY  COPYRIGHT 2000 ACS
RN   210700-56-4  REGISTRY
CN   Androst-5-en-17-one, 3-hydroxy-, (3.beta.,8.alpha.,9.beta.,10.alpha.,
     13.alpha.,14.beta.)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C19 H28 O2
SR   CA
LC   STN Files:   CA, CAPLUS

Absolute stereochemistry.  Rotation (-).
```




```
                1 REFERENCES IN FILE CA (1967 TO DATE)
                1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  129:136350

L78  ANSWER 2 OF 11  REGISTRY  COPYRIGHT 2000 ACS
RN   210700-55-3  REGISTRY
CN   Androst-5-en-17-one, 3-hydroxy-, (3.alpha.,8.alpha.,9.beta.,10.alpha.
     ,13.alpha.,14.beta.)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C19 H28 O2
SR   CA
LC   STN Files:   CA, CAPLUS

Absolute stereochemistry.  Rotation (-).
```

Point of Contact:
Jan Delaval
Librarian-Physical Sciences
CM1 1E01 Tel: 308-4498



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:136350

L78 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN **169333-27-1** REGISTRY
CN Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-, compd. with methanol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methanol, compd. with (3.beta.)-3-hydroxyandrost-5-en-17-one (9CI)
FS STEREOSEARCH
MF C19 H28 O2 . x C H4 O
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

CM 1

CRN 67-56-1
CMF C H4 O

H_3C-OH

CM 2

CRN 53-43-0
CMF C19 H28 O2

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:265915

L78 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN **169333-26-0** REGISTRY
CN Androst-5-en-17-one, 3-hydroxy-, tetrahydrate, (3.beta.)- (9CI) (CA INDEX

NAME)
FS STEREOSEARCH
MF C19 H28 O2 . 4 H2 O
SR CA
LC STN Files: CA, CAPLUS, TOXLIT
CRN (53-43-0)

Absolute stereochemistry. Rotation (+).



●4 H_2O

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:265915

L78 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN 149144-65-0 REGISTRY
CN **Androst-5-en-17-one-17O, 3-hydroxy-, (3.beta.)- (9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF **C19 H28 O2**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 119:90521

L78 ANSWER 6 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN **126910-14-3** REGISTRY
CN Androst-5-en-17-one, 3-hydroxy-, monohydrate, (3.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3.beta.-Hydroxy-5-androsten-17-one monohydrate
FS STEREOSEARCH
MF C19 H28 O2 . H2 O

SR CA
LC STN Files: CA, CAPLUS, TOXLIT
CRN (53-43-0)

Absolute stereochemistry. Rotation (+).



● H_2O

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:265915

REFERENCE 2: 116:34571

REFERENCE 3: 112:208334

L78 ANSWER 7 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN 25375-38-6 REGISTRY
CN **Androst-5-en-17-one, 3-hydroxy- (8CI, 9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF **C19 H28 O2**
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMINFORMRX, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



9 REFERENCES IN FILE CA (1967 TO DATE)
9 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 121:238395

REFERENCE 2: 120:124107

REFERENCE 3: 114:255713

REFERENCE 4: 112:54465

REFERENCE 5: 105:208158

REFERENCE 6: 91:210462

REFERENCE 7: 89:209069

REFERENCE 8: 78:128440

REFERENCE 9: 77:83832

L78 ANSWER 8 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN 24357-33-3 REGISTRY
CN **Androst-5-en-17-one, 3-hydroxy-, (3.beta.,14.beta.)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **14.beta.-Androst-5-en-17-one, 3.beta.-hydroxy- (8CI)**
FS STEREOSEARCH
MF **C19 H28 O2**
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMINFORMRX, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 114:207581

REFERENCE 2: 72:12952

L78 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN 2283-82-1 REGISTRY
CN **Androst-5-en-17-one, 3-hydroxy-, (3.alpha.)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Androst-5-en-17-one, 3.alpha.-hydroxy- (8CI)**
OTHER NAMES:
CN Dehydroandrosterone
CN **Isoandrostenolone**
FS STEREOSEARCH
MF **C19 H28 O2**
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMINFORMRX, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



60 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
60 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:4592

REFERENCE 2: 132:343519

REFERENCE 3: 132:62614

REFERENCE 4: 130:335071

REFERENCE 5: 130:81683

REFERENCE 6: 129:184357

REFERENCE 7: 129:166238

REFERENCE 8: 128:320011

REFERENCE 9: 126:272437

REFERENCE 10: 126:198145

L78 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN 571-35-7 REGISTRY
CN **Androst-5-en-17-one, 3-hydroxy-, (3.beta.,13.alpha.)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **13.alpha.-Androst-5-en-17-one, 3.beta.-hydroxy- (6CI, 7CI, 8CI)**
FS STEREOSEARCH
MF **C19 H28 O2**
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMINFORMRX
(*File contains numerically searchable property data)

Absolute stereochemistry.



10 REFERENCES IN FILE CA (1967 TO DATE)
10 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:66658

REFERENCE 2: 122:214318

REFERENCE 3: 121:205780

REFERENCE 4: 121:133236

REFERENCE 5: 110:24133

REFERENCE 6: 94:15961

REFERENCE 7: 88:105641

REFERENCE 8: 84:5234

REFERENCE 9: 80:15106

REFERENCE 10: 68:33228

L78 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2000 ACS
RN **53-43-0** REGISTRY
CN **Androst-5-en-17-one, 3-hydroxy-, (3.beta.)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Androst-5-en-17-one, 3.beta.-hydroxy- (8CI)**
OTHER NAMES:
CN 17-Chetovis
CN 17-Hormoforin
CN **3.beta.-Hydroxyandrost-5-en-17-one**
CN 5,6-Dehydroisoandrosterone
CN 5,6-Didehydroisoandrosterone
CN 5-Dehydroepiandrosterone
CN **Androstenolone**
CN Dehydro-epi-androsterone
CN Dehydroepiandrosterone
CN Dehydroisoandrosterone
CN DHA
CN **DHEA**
CN Diandron
CN Diandrone
CN Prasterone
CN Psicosterone
CN trans-Dehydroandrosterone
FS STEREOSEARCH
DR 9013-35-8, 105597-37-3, 108673-53-6
MF **C19 H28 O2**
CI COM
LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



5012 REFERENCES IN FILE CA (1967 TO DATE)
103 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5019 REFERENCES IN FILE CAPLUS (1967 TO DATE)
93 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:183007

REFERENCE 2: 133:172310

REFERENCE 3: 133:172301

REFERENCE 4: 133:168384

REFERENCE 5: 133:160079

REFERENCE 6: 133:160061

REFERENCE 7: 133:159895

REFERENCE 8: 133:155534

REFERENCE 9: 133:155470

REFERENCE 10: 133:145427

=> d his

(FILE 'REGISTRY' ENTERED AT 15:50:24 ON 21 SEP 2000)
DEL HIS
ACT QAZI526/A

L1 (1) SEA FILE=REGISTRY ABB=ON PLU=ON DHEA/CN
L2 (532) SEA FILE=REGISTRY ABB=ON PLU=ON C19H28O2/MF AND C5-C6-C6-C6/E
L3 (46) SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND 3 HYDROXY AND 17 ONE A
L4 (10) SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT (LABELED OR ION OR (D
L5 (8) SEA FILE=REGISTRY ABB=ON PLU=ON L4 AND ANDROST
L6 8 SEA FILE=REGISTRY ABB=ON PLU=ON (L1 OR L5)

ACT QAZI526A/A

L7 15 SEA FILE=REGISTRY ABB=ON PLU=ON (149144-65-0/CRN OR 210700-55

FILE 'HCAPLUS' ENTERED AT 15:52:44 ON 21 SEP 2000
ACT QAZI526B/A

L8 (1) SEA FILE=REGISTRY ABB=ON PLU=ON DHEA/CN
L9 (532) SEA FILE=REGISTRY ABB=ON PLU=ON C19H28O2/MF AND C5-C6-C6-C6/E
L10 (46) SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND 3 HYDROXY AND 17 ONE A
L11 (10) SEA FILE=REGISTRY ABB=ON PLU=ON L10 NOT (LABELED OR ION OR (D
L12 (8) SEA FILE=REGISTRY ABB=ON PLU=ON L11 AND ANDROST
L13 (8) SEA FILE=REGISTRY ABB=ON PLU=ON (L8 OR L12)

```
L14 (        15)SEA FILE=REGISTRY ABB=ON  PLU=ON  (149144-65-0/CRN OR 210700-55
L15         7794 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 OR L14 OR DHEA OR DEHYDROE
                 ---------
                   E  PARASRAMPURIA J/AU
L16           34 S E3,E4
                   E YONKER M/AU
                   E SCHWARTZ K/AU
L17           88 S E3,E7,E19,E23
                   E GURWITH M/AU
L18           15 S E3-E6
L19            1 S L15 AND L16-L18
L20          126 S L15 AND ?CRYS?
L21           22 S L15 AND POLYMORPH?
L22            0 S L15 AND POLY MORPH?
L23            4 S L20 AND L21
L24            1 S L23 AND POLYMORPH
L25            2 S L15 AND POLYMORPH
L26            2 S L24,L25
                   SEL RN

     FILE 'REGISTRY' ENTERED AT 16:00:04 ON 21 SEP 2000
L27            7 S E1-E7
L28            4 S L27 AND L6,L7

     FILE 'HCAPLUS' ENTERED AT 16:01:40 ON 21 SEP 2000
L29            8 S L7
L30            7 S L29 NOT L26
L31            1 S L30 AND PHARMACEUT? (L) DOSAG? (L) FORM?/CW
L32            4 S L19,L26,L31
L33            0 S L20 AND EXCIPIENT
L34            3 S L15 AND EXCIPIENT
L35            1 S L34 NOT 64/SC,SX
L36            5 S L32,L35
L37          177 S L15 AND (CRYST? OR MOLECUL?)(L)STRUCTUR?/CW
L38          775 S (L6 OR L7)(L)(THU/RL OR BAC/RL OR PRP/RL)
L39           18 S L38 AND L20
L40           45 S L38 AND L37
L41           58 S L39,L40
L42           16 S L41 AND (1 OR 63 OR 17 OR 18)/SC,SX
L43            6 S (L6 OR L7)(L)FFD/RL
L44            6 S L43 AND L20,L37,L38
L45           64 S L44,L41 AND L15
L46           21 S L45 AND (1 OR 63 OR 17 OR 18)/SC,SX
L47            5 S L36,L44 AND L46
L48            4 S L21 AND FORM
L49            1 S L48 AND 63/SC
L50            6 S L47,L49
L51           21 S L21 NOT L46
L52           12 S L51 NOT 3/SC,SX
L53            1 S L52 AND CRYSTAL STRUCTURE
L54            1 S L52 AND IMMUNE RESPONSE
L55            8 S L50,L53,L54
L56           91 S L38 AND 63/SC,SX
L57           26 S L56 AND (DEHYDROEPIAN? OR DHEA)/TI
L58            4 S L57 AND (DEVICE OR AROMATASE OR INTERLEUKIN OR RETINOID)/TI
L59           22 S L57 NOT L58
L60           21 S L59 NOT CLATHRATE
L61           43 S L15 AND ?TABLET?
L62           61 S L15 AND ?CAPSUL?
L63           86 S L61,L62
L64            6 S L63 AND L20
L65            1 S L64 AND ANTIULCER
L66            9 S L55,L65
L67          181 S L15 AND (?GASTRO? OR ?GASTRI? OR ?INTESTIN? OR STOMACH OR DIG
L68            4 S L63 AND L67
L69            1 S L68 AND CONJUGATED/TI
```

```
L70          10 S L66,L69
L71          83 S L63 NOT L70
L72          24 S L71 AND 63/SC
L73          22 S L72 NOT L59
L74           5 S L73 AND (DYSTROPHY OR DELIVERY)/TI
L75           2 S L74 NOT (MUCOSAL OR COMPLEXES OR CYCLODEXTRIN)/TI
L76          12 S L70,L75
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 16:35:09 ON 21 SEP 2000
L77           4 S E8-E11
L78          11 S L6,L77

     FILE 'REGISTRY' ENTERED AT 16:36:17 ON 21 SEP 2000

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:36:32 ON 21 SEP 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1967 - 21 Sep 2000  VOL 133 ISS 13
FILE LAST UPDATED: 20 Sep 2000  (20000920/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REG1stRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

Now you can extend your author, patent assignee, patent information,
and title searches back to 1907.  The records from 1907-1966 now have
this searchable data in CAOLD.  You now have electronic access to all
of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.

=> d l76 all tot

L76  ANSWER 1 OF 12  HCAPLUS  COPYRIGHT 2000 ACS
AN   1999:600454  HCAPLUS
DN   132:136719
TI   Dehydroepiandrosterone: a nutritional supplement with actions in
     the central nervous system
AU   Svec, Frank; Porter, Johnny R.
CS   Obesity Research Program, Departments of Medicine and Physiology, LSU
     Medical School, New Orleans, LA, 70112, USA
SO   Nutr. Neurosci. (1998), 1(1), 9-19
     CODEN: NNINFE; ISSN: 1028-415X
PB   Harwood Academic Publishers
DT   Journal; General Review
LA   English
CC   18-0 (Animal Nutrition)
AB   A review with 50 refs.  Dehydroepiandrosterone is now available
     to the general US population as a dietary supplement.  Although
     advertising of any health benefit is restricted, many people take it for
     purported salutary effects on age-related processes.  One of these
     benefits is the delay of Alzheimer disease onset.  This review evaluates
     the data from animal and human trials on DHEA effects.
     DHEA is active in the central nervous system when given
     exogenously, is made in the central nervous system of lab. animals, and
```

may have a role in regulating normal physiol. processes. Possible cellular mechanisms of action are described. **DHEA** may have particular effects on learning and memory in test animals, but there are only sparse data in humans where observations are indirect and poorly controlled. The data are compelling enough to warrant further research, although it is premature to suggest a safe trial dosing schedule for this steroid hormone in humans.

ST review **dehydroepiandrosterone** nutrition supplement physiol brain aging

IT Nervous system
(central; **dehydroepiandrosterone** as nutritional supplement with actions in central nervous system and aging processes)

IT Aging, animal
Nutrition, animal
(**dehydroepiandrosterone** as nutritional supplement with actions in central nervous system and aging processes)

IT **53-43-0, Dhea**
RL: **BAC (Biological activity or effector, except adverse)**; **FFD (Food or feed use)**; BIOL (Biological study); USES (Uses)
(**dehydroepiandrosterone** as nutritional supplement with actions in central nervous system and aging processes)

RE.CNT 50

RE

(1) Abadie, J; Diabetes 1993, V42, P662 HCAPLUS
(2) Akwa, Y; Journal of Steroid Biochemical Molecular Biology 1991, V40, P71 HCAPLUS
(3) Azuma, T; Journal of Neurological Science 1993, V120, P87 MEDLINE
(4) Barrett-Connor, E; Journal of the American Geriatrics Society 1994, V42, P420 MEDLINE
(5) Baulieu, E; Biology of the Cell 1991, V71, P3 HCAPLUS
(6) Bergeron, R; Journal of Neuroscience 1996, V16, P1193 HCAPLUS
(7) Birkenhager-Gillesse, E; Annals of the New York Academy of Science 1994, V719, P543 HCAPLUS
(8) Calabrese, V; The Biologic Role of Dehydroepiandrosterone (DHEA) 1990, P95
(9) Corpechot, C; Proceedings of the National Academy of Science USA 1981, V78, P4704 HCAPLUS
(10) Demirgoren, S; Neuroscience 1991, V45, P127 HCAPLUS
(11) Diamond, D; Neuroscience Letters 1996, V202, P204 HCAPLUS
(12) Ebeling, P; Lancet 1994, V343, P1479 MEDLINE
(13) Flood, J; Proceedings of the National Academy of Science USA 1992, V89, P1567 HCAPLUS
(14) Friess, E; American Journal of Physiology 1995, V268, PE107 HCAPLUS
(15) Garcia de Yebenes, E; Journal of Neuroendocrinology 1995, V7, P589 MEDLINE
(16) Haug, M; Physiology and Behavior 1989, V46, P955 HCAPLUS
(17) Hung, T; Journal of Steroid Biochemistry 1988, V29, P721 HCAPLUS
(18) Jo, D; Steroids 1989, V54, P287 HCAPLUS
(19) Kalimi, M; Molecular and Cellular Biochemistry 1994, V131, P99 HCAPLUS
(20) Labrie, C; Journal of Endocrinology 1996, V150(Suppl), PS107
(21) Lacroix, C; Journal of Steroid Biochemistry 1987, V28, P317 HCAPLUS
(22) Leblhuber, F; Psychopharmacology 1993, V111, P23 HCAPLUS
(23) Legrain, S; Gerontology 1995, V41, P343 HCAPLUS
(24) Li, S; Peptides 1995, V16, P425 HCAPLUS
(25) Longcope, C; Steroids 1996, V61, P7 HCAPLUS
(26) Mathur, C; Proceedings of the National Academy of Science USA 1993, V90, P85 HCAPLUS
(27) Meaney, M; Experimental Gerontology 1995, V30, P229 HCAPLUS
(28) Meikle, A; Journal of Steroid Biochemistry and Molecular Biology 1992, V42, P293 HCAPLUS
(29) Melchior, C; Pharmacology Biochemistry and Behavior 1992, V43, P223 HCAPLUS
(30) Melchior, C; Pharmacology Biochemistry and Behavior 1994, V47, P437 HCAPLUS
(31) Meyer, J; Brain Research 1994, V633, P253 MEDLINE
(32) Morales, A; Journal of Clinical Endocrinology and Metabolism 1994, V78, P1360 HCAPLUS
(33) Nasman, B; Biological Psychiatry 1991, V30, P684 MEDLINE

(34) Nasman, B; Psychoneuroendocrinology 1995, V20, P83 MEDLINE
(35) Parker, L; Adrenal Androgens in Clinical Medicine 1989, P450
(36) Porter, J; Annals of New York Academy of Science 1995, V774, P329 HCAPLUS
(37) Porter, J; International Journal of Obesity 1995, V19, P480 HCAPLUS
(38) Prasad, A; Journal of Investigative Medicine 1996, V44, P6A
(39) Prasad, C; Brain Research 1995, V699, P149 HCAPLUS
(40) Robel, P; Journal of Steroid Biochemistry 1987, V27, P649 HCAPLUS
(41) Roberts, E; Brain Research 1987, V406, P357 HCAPLUS
(42) Salahuddin, F; Journal of Investigative Medicine 1997, V45, P56A
(43) Schumacher, M; Developmental Neuroscience 1996, V18, P6 HCAPLUS
(44) Singh, V; Molecular and Cellular Neurosciences 1994, V5, P176 HCAPLUS
(45) Sunderland, T; Lancet 1989, Vii(8662), P570
(46) Svec, F; Current Opinion in Endocrinology and Diabetes 1996, V3, P117 HCAPLUS
(47) Wolkowitz, O; Biological Psychiatry 1997, V41, P311 HCAPLUS
(48) Wright, B; International Journal of Obesity 1995, V19, P887 HCAPLUS
(49) Yamada, J; Biochimica et Biophysica Acta 1994, V1224, P139 HCAPLUS
(50) Yoo, A; Experimental Neurology 1996, V137, P151 HCAPLUS

L76 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1999:191402 HCAPLUS
DN 130:213663
TI **DHEA**-containing nutritional supplement
IN Craft, John C.
PA USA
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-595
NCL 514168000
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): **18**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883086	A	19990316	US 1997-850850	19970502

AB The present invention relates to a nutritional supplement contg. from 5% to 2000% each of the RDA of vitamins A, C, D, E and .beta.-carotene, from 5% to 500% of the RDA of the minerals selenium, zinc, magnesium, calcium, iodine and potassium, from 5 to 100 mg **dehydroepiandrosterone** (**DHEA**), from 0.1-10 mg trans-ferulic acid, and one or more plant exts. selected from ginseng and garlic. These **DHEA**-contg. nutritional supplements are useful in the alleviation of an irregular heartbeat as well as the general symptoms of stress.
ST **DHEA** nutritional supplement heart arrhythmia stress; vitamin mineral aspirin **DHEA** supplement arrhythmia stress
IT Arrhythmia
Capsules (drug delivery systems)
Drug delivery systems
Garlic (Allium sativum)
Ginseng (Panax)
Powders (drug delivery systems)
Stress (animal)
Suppositories (drug delivery systems)
Tablets (drug delivery systems)
(**DHEA**-contg. nutritional supplement for arrhythmia and stress treatment)
IT Mineral nutrients, biological studies
Vitamins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**DHEA**-contg. nutritional supplement for arrhythmia and stress treatment)
IT 50-78-2, Acetylsalicylic acid 50-81-7, Vitamin C, biological studies
53-43-0, **DHEA** 68-19-9, Vitamin B12 537-98-4,

trans-Ferulic acid 1406-16-2, Vitamin D 1406-18-4, Vitamin E 7235-40-7, .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological studies 7440-09-7, Potassium, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7553-56-2, Iodine, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 11103-57-4, Provitamin A
RL: **FFD (Food or feed use)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**DHEA**-contg. nutritional supplement for arrhythmia and stress treatment)

RE.CNT 6
RE
(1) Andon; US 5571441 1996
(2) Benjamin; US 4837239 1989
(3) Masor; US 5488039 1996
(4) Sakai; Teratogenesis Carcinogenesis & Mutagenesis 1994, V14, P219 HCAPLUS
(5) Steele; J Cellular Biochem 1994, V20(Suppl), P32
(6) Weischer; US 5569670 1996

L76 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1999:106987 HCAPLUS
DN 130:158397
TI Sleep-promoting compositions containing **dehydroepiandrosterones**
IN Tanizawa, Shigeharu; Kan, Chihoko; Hirayama, Masaya
PA Pola Chemical Industries, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C07J019-00
CC **63-5** (Pharmaceuticals)
Section cross-reference(s): **17**, 62
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11035596	A2	19990209	JP 1997-205361	19970715

AB Sleep-promoting compns. (e.g. foods, cosmetics, and oral and topical drugs) contain **dehydroepiandrosterone** (I) and/or its derivs. A cream contg. I was useful in treating sleep disorders.
ST sleep promoter **dehydroepiandrosterone** food cosmetic
IT Cosmetics
Food
Hypnotics and Sedatives
Oral drug delivery systems
Topical drug delivery systems
(sleep-promoting compns. contg. **dehydroepiandrosterones**)
IT **53-43-0, Dehydroepiandrosterone 53-43-0D, Dehydroepiandrosterone**, derivs. 521-17-5, Androstenediol 4150-30-5, Androstenetriol
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BUU (Biological use, unclassified); **FFD (Food or feed use)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sleep-promoting compns. contg. **dehydroepiandrosterones**)

L76 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1998:754926 HCAPLUS
DN 130:144260
TI Quality control of **dehydroepiandrosterone** dietary supplement products
AU **Parasrampuria, J.**; **Schwartz, K.**; Petesch, R.
CS Genelabs Technologies, Inc., Redwood City, CA, USA
SO JAMA, J. Am. Med. Assoc. (1998), 280(18), 1565
CODEN: JAMAAP; ISSN: 0098-7484
PB American Medical Association

DT Journal
LA English
CC 64-3 (Pharmaceutical Analysis)
Section cross-reference(s): **17**
AB To asses the accuracy of manufacturers' label claims, **dehydroepiandrosterone** (**DHEA**) products available at health food stores in the US were analyzed by HPLC. Only half the products tested met manufacturers' label claims and some products contained no **DHEA** or, in one case, contained 150% of the amt. claimed on the label.
ST **dehydroepiandrosterone** detn HPLC dietary product
IT HPLC
(quality control of **dehydroepiandrosterone** dietary supplement products)
IT **53-43-0, Dehydroepiandrosterone**
RL: ANT (Analyte); **FFD (Food or feed use); THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(quality control of **dehydroepiandrosterone** dietary supplement products)
RE.CNT 6
RE
(1) Anon; Public Law 1994, P103
(2) Labrie, F; Ann NY Acad Sci 1995, V774, P16 HCAPLUS
(3) Mortola, J; J Clin Endocrinol Metab 1990, V71, P696 HCAPLUS
(4) Skolnick, A; JAMA 1996, V276, P1365 MEDLINE
(5) US Government Printing Office; Code of Federal Regulations Food and Drug 1998
(6) Young, J; J Clin Endocrinol Metab 1997, V82, P2578 HCAPLUS

L76 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1996:608827 HCAPLUS
DN 125:261814
TI Investigations of **dehydroepiandrosterone**. I. **Crystal structure** of sublimed **DHEA**
AU Bhacca, Norman S.; Fronczek, Frank R.; Sygula, Andrzej
CS Department Chemistry, Louisiana State Univ., Baton Rouge, LA, 70803-1804, USA
SO J. Chem. Crystallogr. (1996), 26(7), 483-487
CODEN: JCCYEV; ISSN: 1074-1542
DT Journal
LA English
CC 75-8 (Crystallography and Liquid Crystals)
Section cross-reference(s): 32
AB The **crystal structure** of an orthorhombic **polymorph** of the title compd., crystd. by sublimation, was detd. **Dehydroepiandrosterone**, C19H28O2, is orthorhombic, space group P212121, with a 6.6408(4) b 11.4423(11) c 22.085(2) .ANG.3, Z = 4, dc = 1.141, R = 0.051 for 2645 obsd. reflections. At. coordinates are given. The conformation of the mol. is similar to that found in other **polymorphs** and solvates, with a chair A ring, an 8.beta.,9.alpha. half-chair B ring, a chair C ring, and a 14.alpha. envelope D ring. Mols. are linked in chains by OH ... O H bonds involving the carbonyl O atom. The O ... O distance is 2.855(3) .ANG., and the angle about H is 171(2).degree..
ST mol structure **dehydroepiandrosterone**
IT **Crystal structure**
Molecular structure
(of **dehydroepiandrosterone**)
IT **53-43-0, Dehydroepiandrosterone**
RL: PRP (Properties)
(**crystal structure** of)

L76 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1996:363395 HCAPLUS
DN 125:19021
TI Remedy for myotonic **dystrophy**

IN Ohsawa, Nakaaki; Sugino, Masakazu; Endo, Tomio
PA Kanebo, Ltd., Japan
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K031-565
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9604917	A1	19960222	WO 1995-JP1561	19950807
W: CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08048630	A2	19960220	JP 1994-205939	19940808
JP 2698865	B2	19980119		
EP 776663	A1	19970604	EP 1995-927977	19950807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5834451	A	19981110	US 1997-776888	19970415

PRAI JP 1994-205939 19940808
WO 1995-JP1561 19950807

AB A remedy for myotonic dystrophy contains **dehydroepiandrosterone** sulfate or a pharmacol. acceptable salt thereof, being efficacious for myotonia, adynamia and amyotriphy, and having a high safety. **Capsules** were formulated contg. Na **dehydroepiandrosterone** sulfate dihydrate 546, mannitol 144, and magnesium stearate 10 g. The prens. were clin. tested and showed minimal side effects.
ST myotonic dystrophy **dehydroepiandrosterone** sulfate
IT Pharmaceutical dosage forms
(**capsules**, compns. contg. **dehydroepiandrosterone** sulfate for treatment of myotonic dystrophy)
IT Pharmaceutical dosage forms
(injections, compns. contg. **dehydroepiandrosterone** sulfate for treatment of myotonic dystrophy)
IT Muscular dystrophy
(myotonic, compns. contg. **dehydroepiandrosterone** sulfate for treatment of myotonic dystrophy)
IT Pharmaceutical dosage forms
(suppositories, compns. contg. **dehydroepiandrosterone** sulfate for treatment of myotonic dystrophy)
IT Pharmaceutical dosage forms
(**tablets**, compns. contg. **dehydroepiandrosterone** sulfate for treatment of myotonic dystrophy)
IT 651-48-9, **Dehydroepiandrosterone** sulfate 1099-87-2, Sodium **dehydroepiandrosterone** sulfate 78590-17-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. **dehydroepiandrosterone** sulfate for treatment of myotonic dystrophy)

L76 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1996:304720 HCAPLUS
DN 125:1449
TI Pleiotropic effects of dietary **DHEA**
AU Milewich, Leon; Catalina, Fernando; Bennett, Michael
CS Southwestern Medical Center, University of Texas, Dallas, TX, 75235, USA
SO Ann. N. Y. Acad. Sci. (1995), 774(Dehydroepiandrosterone (DHEA) and Aging), 149-170
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal; General Review
LA English
CC 2-0 (Mammalian Hormones)
Section cross-reference(s): **18**
AB A review, with 33 refs., of data pertaining to some of the in vivo effects assocd. with dietary **DHEA** administration. Specific topics discussed were: reduced wt. gain, hepatomegaly, and liver color change;

hepatic approx. 72 kD protein induced by **DHEA**; **DHEA** effect on hepatic enzyme activities; peroxisomal proliferation; hepatic ultrastructure; dietary **DHEA** and hepatic lipogenic enzymes; **DHEA** effects on rates of hepatic fatty acid and cholesterol synthesis; **DHEA**, hepatic mitochondria, and the urea cycle; hepatic glutathione S-transferase and dietary **DHEA**; **DHEA** effects on hepatic endogenous protein phosphorylation; **DHEA** effects on liver phosphatase; **DHEA** metab. by rodent liver microsome; and dietary **DHEA** effect on serum prolactin in mice.

ST review dietary **DHEA** pleotropic effect

IT **53-43-0**, **DHEA**
RL: **BAC (Biological activity or effector, except adverse)**; BPR (Biological process); **FFD (Food or feed use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(pleiotropic effects of dietary **DHEA**)

L76 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1995:790818 HCAPLUS
DN 123:265915
TI Solid State Characterization of **Dehydroepiandrosterone**
AU Chang, Luh-Chian; Caira, Mino R.; Guillory, J. Keith
CS College of Pharmacy, University of Iowa, Iowa City, IA, 52242, USA
SO J. Pharm. Sci. (1995), 84(10), 1169-79
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
CC **63-5** (Pharmaceuticals)
Section cross-reference(s): 32, 69

AB Three **polymorphs** (**forms** I-III), a monohydrate (**form** S2), and three new solvates [4:1 hydrate (**form** S1), monohydrate (**form** S3), and methanol half-solvate (**form** S4)] were isolated and characterized by X-ray powder diffractometry (XRPD), IR spectroscopy, differential scanning calorimetry (DSC), hot stage microscopy, soln. calorimetry, and their dissoln. rates. A new **polymorph**, designated as **form** V, melting at 146.5-148.degree., was obsd. by hot stage microscopy. The results indicate that only **forms** I and S4 exhibit reproducible DSC thermograms. Five of the isolated modifications undergo phase transformation on heating, and their DSC thermograms are not reproducible. Interpretation of DSC thermograms was facilitated by use of hot stage microscopy. The identification of each modification is based on XRPD patterns (except **forms** S3 and S4, for which the XRPD patterns are indistinguishable) and IR spectra. In the IR spectra, a significant difference was obsd. in the OH stretching region for all seven modifications. In a purity detn. study, 5% of a contaminant modification in binary mixts. of several modifications could be detected by use of XRPD. To obtain a better understanding of the thermodn. properties of these modifications, a series of increasing heating rates and different pan types were used in DSC. According to Burger's rule, **forms** I-III are monotropic **polymorphs** with decreasing stability in the order **form** I > **form** II > **form** III. The melting onsets and heats of fusion for **forms** I-III are 149.1.degree., 25.5 kJ/mol; 140.8.degree., 24.6 kJ/mol; and 137.8.degree., 24.0 kJ/mol, resp. For **form** III the heat of fusion was calcd. from heat of soln. and DSC data. In the case of **form** S1 the m.p., 127.2.degree., was obtained by DSC using a hermetically sealed pan. The relative stabilities of the six modifications stored under high humidity conditions were predicted to be, on the basis of the heat of soln. and thermal anal. data, **form** S2 > **form** S3 > **form** S1 > **form** I > **form** II > **form** III. However, the results of the dissoln. rate detn. were inconsistent with the heat of soln. data. The stable **form** I shows a higher initial dissoln. rate than the metastable **form** II and unstable **form** III. All modifications were converted into the stable monohydrate, **form** S2, during the dissoln. study, suggesting that the moisture level in solid formulations should be carefully controlled.

ST **dehydroepiandrosterone polymorph** solvate
IT Entropy
(of fusion; solid state characterization of **dehydroepiandrosterone**)
IT Heat of fusion and Heat of freezing
Heat of hydration and Heat of dehydration
Heat of solution
Heat of transition
Polymorphism
Solution rate
(solid state characterization of **dehydroepiandrosterone**)
IT **126910-14-3 169333-26-0 169333-27-1**
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
(solid state characterization of **dehydroepiandrosterone**)
IT 67-56-1, Methanol, uses
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(solid state characterization of **dehydroepiandrosterone**)
IT **53-43-0, Dehydroepiandrosterone**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid state characterization of **dehydroepiandrosterone**)
IT 7732-18-5, Water, reactions
RL: RCT (Reactant)
(solid state characterization of **dehydroepiandrosterone**)
IT 64-17-5, Ethanol, uses
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(solvent; solid state characterization of **dehydroepiandrosterone**)

L76 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1995:96810 HCAPLUS
DN 122:142528
TI **Antiulcer tablets** or injections containing **dehydroepiandrosterone** sulfate as active ingredient
IN Uehara, Satoshi; Hara, Hideaki
PA Kanebo Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K031-565
ICA C07J001-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06183979	A2	19940705	JP 1992-355983	19921218

AB **Antiulcer tablets** or injections contain **dehydroepiandrosterone** sulfate as active ingredient. Thus, **tablets** with low toxicity were formulated contg. sodium **dehydroepiandrosterone** sulfate 500, lactose 100, corn starch 300, **cryst.** cellulose 80, hydroxypropyl cellulose 10, and magnesium stearate 10g. **Dehydroepiandrosterone** sulfate administered s.c. inhibited stress-induced peptic ulcer in rats.
ST **antiulcer tablet** injection
dehydroepiandrosterone sulfate
IT Ulcer inhibitors
(**antiulcer tablets** or injections contg. **dehydroepiandrosterone** sulfate as active ingredient)
IT Pharmaceutical dosage forms
(injections, **antiulcer tablets** or injections contg. **dehydroepiandrosterone** sulfate as active ingredient)
IT Pharmaceutical dosage forms
(**tablets, antiulcer tablets** or injections

contg. **dehydroepiandrosterone** sulfate as active ingredient)
IT 651-48-9, **Dehydroepiandrosterone** sulfate 1099-87-2, Sodium **dehydroepiandrosterone** sulfate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antiulcer tablets** or injections contg. **dehydroepiandrosterone** sulfate as active ingredient)

L76 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1992:100163 HCAPLUS
DN 116:100163
TI Use of **dehydroepiandrosterone** to improve **immune response**
IN Loria, Roger M.; Regelson, William
PA USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A01N045-00
ICS A61K031-565; A61K009-08; A61K009-48
NCL 514171000
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 15
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5077284	A	19911231	US 1988-291969	19881230
	US 5407684	A	19950418	US 1991-733198	19910719
	AU 9222650	A1	19931118	AU 1992-22650	19920414
	EP 637203	A1	19950208	EP 1992-915585	19920414
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 07508264	T2	19950914	JP 1992-518261	19920414
	US 5461042	A	19951024	US 1994-176234	19940103

PRAI US 1988-291969 19881230
US 1989-437903 19891117
US 1991-685078 19910415
WO 1992-US3076 19920414
US 1992-917720 19920724
US 1993-95431 19930723

AB The **immune response** to infectious agents and immunogens is increased in a mammal by administration of **dehydroepiandrosterone** (I) to up-regulate the host immune system against infection. I reduced mortality to 37% from .apprx.90% in untreated animals infected with human coxsackievirus B4 (CVB4). Protection from lethal CVB4 and herpes simplex virus 2 was obsd. with I s.c. injection at 1 g/kg and feeding at 0.4% concn.

ST **dehydroepiandrosterone** immunostimulant; virus infection **immune response dehydroepiandrosterone**
IT Antibodies
RL: BIOL (Biological study)
(cells forming, virus infection and **dehydroepiandrosterone** effect on, in mice)
IT Hematopoietic precursor cell
(coxsackievirus B4 infection and **dehydroepiandrosterone** effect on, in mice)
IT Immunostimulants
(**dehydroepiandrosterone** as, against infectious agents)
IT Feed
(**dehydroepiandrosterone** in, virus infection treatment with, immune system up-regulation in relation to)
IT Antigens
RL: BIOL (Biological study)
(**immune response** to, **dehydroepiandrosterone** effect on)
IT Infection
Mycosis

(immunostimulation against, with **dehydroepiandrosterone**)
IT Parasite
Prion
Viroid
Virus
(infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Spleen, composition
(lymphocytes of, coxsackievirus B4 infection and **dehydroepiandrosterone** effect on, in mice)
IT Injectors
(s.c., of **dehydroepiandrosterone**, virus infection treatment with, immune system up-regulation in relation to)
IT Acquired immune deficiency syndrome
(treatment of, with **dehydroepiandrosterone**, immune system up-regulation in relation to)
IT Immunity
(up-regulation of, with **dehydroepiandrosterone**)
IT Acquired immune deficiency syndrome
(-related complex, treatment of, with **dehydroepiandrosterone**, immune system up-regulation in relation to)
IT Lymphocyte
(B-cell, disease, infection, with coxsackievirus B4, **dehydroepiandrosterone** effect on, in mice)
IT Virus, animal
(Coxsackie B4, infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Virus, animal
(DNA-contg., infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Immunoglobulins
RL: BIOL (Biological study)
(G, cells forming, virus infection and **dehydroepiandrosterone** effect on, in mice)
IT Immunoglobulins
RL: BIOL (Biological study)
(M, cells forming, virus infection and **dehydroepiandrosterone** effect on, in mice)
IT Virus, animal
(RNA-contg., infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Monocyte
(disease, infection, with coxsackievirus B4, **dehydroepiandrosterone** effect on, in mice)
IT Virus, animal
(herpes simplex 2, infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Virus, animal
(human immunodeficiency, infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Virus, animal
(human immunodeficiency 1, infection with, immunostimulation against, with **dehydroepiandrosterone**)
IT Lymphocyte
(plasma cell, virus infection and **dehydroepiandrosterone** effect on, in mice)
IT Leukocyte
(**polymorphonuclear**, coxsackievirus B4 infection and **dehydroepiandrosterone** effect on, in mice)
IT **53-43-0, Dehydroepiandrosterone**
RL: BIOL (Biological study)
(as immunostimulant against infectious agents and immunogens)

L76 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1976:499185 HCAPLUS
DN 85:99185

TI **Dehydroepiandrosterone**-containing drug for aiding " **delivery**
IN Utsumi, Isamu; Endo, Tomio; Kamata, Tadaski; Ando, Masayasu
PA Kanebo, Ltd., Japan
SO Belg., 14 pp.
CODEN: BEXXAL
DT Patent
LA French
IC A64K
CC **63-6** (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 833394	A1	19751231	BE 1975-160028	19750912
	US 4005200	A	19770125	US 1975-596741	19750717
	ZA 7505692	A	19760825	ZA 1975-5692	19750905
	DE 2540131	A1	19770210	DE 1975-2540131	19750909
	DE 2540131	C2	19881103		
	AU 7584703	A1	19770317	AU 1975-84703	19750910
	AU 498673	B2	19790322		
	FR 2317933	A1	19770211	FR 1975-27827	19750911
	FR 2317933	B1	19800425		
	JP 52012933	A2	19770131	JP 1976-381	19760101
	JP 55027884	B4	19800724		
	IL 49948	A1	19791031	IL 1976-49948	19760701
	NL 7607902	A	19770119	NL 1976-7902	19760716

PRAI US 1975-596741 19750717
GI



I

AB Prepns. contg. **dehydroepiandrosterone** sulfate (I) [651-48-9] or another of its salts enhance cervical ripeness and uterine sensitivity to oxytocin [50-56-6] during parturition. For example, **tablets** were prepd. contg. I 50.0, lactose 182.5, talc 2.5, starch 12.5 and Mg stearate 2.5 mg.
ST androsterone deriv parturition; **dehydroepiandrosterone** parturition
IT Uterus
(**dehydroepiandrosterone** effect on, in parturition)
IT Parturition
(**dehydroepiandrosterone** enhancement of)
IT 651-48-9 1099-87-2
RL: BIOL (Biological study)
(parturition improvement by)
IT 50-56-6
RL: BIOL (Biological study)
(uterus response to, in parturition, **dehydroepiandrosterone** enhancement of)

L76 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2000 ACS
AN 1970:24626 HCAPLUS
DN 72:24626
TI Coated **conjugated** neutral steroid sulfates medicament nucleus
IN Oertel, Georg W.; Muenzel, Kurt
PA Hoffmann-La Roche, F., und Co., A.-G.

SO S. African, 8 pp.
CODEN: SFXXAB
DT Patent
LA English
CC 63 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6804390		19690128		
PRAI	CH		19670728		

AB The medicament is coated with a **gastric** juice-resistant layer. Thus, a mixt. of Na **dehydroepiandrosterone** sulfate 10, lactose 50, corn s tarch 13.5, talc 1.35, and Mg stearate 0.15 mg is formed into a **tablet** to which 25 layers (totaling 10 mg) are applied with a soln. contg. cellulose acetate phthalate 10, triacetin 3, EtOH 10, and methylene chloride 77 parts. The product is used for oral administration in conditions of hormonal inbalance.
ST steroid **tablets**; **tablets** steroid
IT Steroids, uses and miscellaneous
RL: USES (Uses)
(sulfates, coating of)
IT 1099-87-2
RL: BIOL (Biological study)
(coating of)

=> fil wpids
FILE 'WPIDS' ENTERED AT 16:47:07 ON 21 SEP 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE LAST UPDATED: 18 SEP 2000 <20000918/UP>
>>>UPDATE WEEKS:
MOST RECENT DERWENT WEEK 200045 <200045/DW>
DERWENT WEEK FOR CHEMICAL CODING: 200045
DERWENT WEEK FOR POLYMER INDEXING: 200045
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS -
SEE HELP COST <<<

>>> FOR UP-TO-DATE INFORMATION ABOUT ALL 'NEW CONTENT' CHANGES TO WPIDS, INCLUDING THE DERWENT CHEMISTRY RESOURCE (DCR), PLEASE VISIT http://www.derwent.com/newcontent.html <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://www.derwent.com/covcodes.html <<<

=> d all abeq tot

L96 ANSWER 1 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 2000-505790 [45] WPIDS
DNN N2000-374048 DNC C2000-151775
TI New buccal dosage units comprising a bioerodible polymeric carrier incorporating a pharmacologically active agent such as an androgenic agent.
DC A96 B01 B04 B07 P32
IN PLACE, V A
PA (PLAC-I) PLACE V A
CYC 89
PI WO 2000042959 A1 20000727 (200045)* EN 32p A61F013-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

ADT WO 2000042959 A1 WO 2000-US1534 20000121
PRAI US 1999-236892 19990126
IC ICM A61F013-00
ICS **A61K009-22**
AB WO 200042959 A UPAB: 20000918
NOVELTY - New buccal dosage units comprise a bioerodible polymeric carrier incorporating a pharmacologically active agent.
DETAILED DESCRIPTION - A novel compact buccal dosage unit for administering a pharmacologically active agent comprises a uniform composition of a bioerodible polymeric carrier which upon sustained contact with the buccal mucosa completely erodes within a predetermined drug delivery period of 4-24 hours, and having incorporated, a pharmacologically active agent, where the total weight of the units is less than or equals 40 mg.
INDEPENDENT CLAIMS are also included for the following:
(1) a buccal dosage unit for administering an androgenic agent, comprising a 5-20 mg **tablet** containing 40 - 80 wt.% testosterone in a bioerodible polymeric carrier, which upon contact with the buccal mucosa erodes within 8-24 hours;
(2) a dosage unit for administering a pharmacologically active agent, consisting of a pharmacologically active agent, a bioerodible polymeric carrier which gradually and completely erodes upon prolonged contact with the buccal mucosa, and 0.01 - 2.0 wt.% of a lubricant;
(3) a method for administering a pharmacologically active agent to a mammalian individual by affixing a buccal drug delivery system to the buccal mucosa of the individual, the improvement comprising affixing the system to a region of the upper gum between the first bicuspid on the left and the first bicuspid on the right.
ACTIVITY - Androgenic.
MECHANISM OF ACTION - Androgen supplement.
USE - The dosage units can be used for administering a pharmacological agent to a mammal (claimed). The compositions containing an androgenic agent can be used for effecting hormone replacement therapy or treating sexual dysfunction in a mammalian male individual (claimed). They can also be used for treating an androgen-responsive disorder, especially. hypogonadism (claimed). They can also be used for the delivery of contraceptive agents.
ADVANTAGE - The dosage unit adheres well to the buccal mucosa, is small enough so as not to cause patient discomfort, and completely hydrolyzes within the mouth, i.e. gradually and completely bioerodes throughout the drug delivery period.
DESCRIPTION OF DRAWING(S) - The figure shows a graph representing free testosterone plasma levels as a function of time, following administration of either a placebo or a T1-1 or T2-1 buccal testosterone **tablet**.
Dwg.2/7
FS CPI GMPI
FA AB; GI; DCN
MC CPI: A09-A07; A12-V01; B01-C05; B04-C03; **B12-M11B**; B14-D01A

L96 ANSWER 2 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1999-629219 [54] WPIDS
DNC C1999-183564
TI Hormone containing external preparation compositions - contains **dehydro epiandrosterone** and one or more additives.
DC B05
PA (SAIT-N) SAITAMA DAIICHI SEIYAKU KK
CYC 1
PI JP 11279064 A 19991012 (199954)* 5p A61K031-56
ADT JP 11279064 A JP 1998-86695 19980331
PRAI JP 1998-86695 19980331
IC ICM A61K031-56
ICS **A61K009-08**; A61K047-10; A61K047-14; A61K047-22
AB JP 11279064 A UPAB: 19991221
An external preparation composition contains: (A) **dehydroepiandrosterone**; and (B) one or more kinds selected from

7-12C alkane, N-alkyl-2-pyrrolidone, terpenes, diisopropyl adipate, higher alcohol, polyhydric alcohol and mono-fatty acid glyceride.

USE - The composition is useful for prevention and treatment of e.g. cancer, obesity, diabetes, retroviral infectious diseases, hyperlipidaemia, melancholia, memory disorder and progressive necrosis.

ADVANTAGE - The composition gives excellent absorbability of **dehydroepiandrosterone**.

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B01-D02; B07-D02; B10-E04C; B10-E04D; B10-G02; B10-J02; B14-A02B1; B14-E12; B14-F06; B14-H01; B14-J01A4; B14-S04

L96 ANSWER 3 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1999-550826 [46] WPIDS
DNC C1999-160620
TI A composition comprising one or more hormone(s), amino acid(s), enzyme(s) and/or vitamin(s) and mineral (s) for treatment of the human body - used to treat cardiovascular, autoimmune diseases and Parkinson's disease.
DC B05
IN COCHRAN, T M; COCHRAN, T
PA (COCH-I) COCHRAN T; (COCH-I) COCHRAN T M
CYC 84
PI WO 9943329 A1 19990902 (199946)* EN 54p A61K031-56
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW
AU 9927901 A 19990915 (200004) A61K031-56
US 6048846 A 20000411 (200025) A61K031-595
ADT WO 9943329 A1 WO 1999-US4130 19990225; AU 9927901 A AU 1999-27901 19990225; US 6048846 A US 1998-31227 19980226
FDT AU 9927901 A Based on WO 9943329
PRAI US 1998-31227 19980226
IC ICM A61K031-56; A61K031-595
ICS **A61K009-48**; A61K033-20; A61K033-26; A61K033-30; A61K033-32
AB WO 9943329 A UPAB: 19991110
NOVELTY - A composition for treating the human body comprises at least one hormone, amino acid, enzyme and/or vitamin and at least one mineral with relative proportions such that they are balanced with respect to each other for restoring optimal levels in the body and also operating synergistically to provide nutrients and command/regulatory components enabling the body to effectively utilize them.

USE - The composition is used to restore levels of hormone, amino acid, enzyme and mineral to the optimum in the body to maintain the health of the body and fight disease. The composition is useful for treating cardiovascular diseases, autoimmune diseases, Parkinson's disease etc. The composition may also prove to be useful in the treatment of Lupus and Fibromyalgia syndrome, chronic fatigue syndrome and rheumatoid arthritis.

Dwg.0/8

FS CPI
FA AB; DCN
MC CPI: B03-L; B04-J02; B04-L05C; B05-A02; B05-A03; B10-B02C; B14-C09B; B14-D01; B14-F01; B14-G01; B14-G02D; B14-J01A3

L96 ANSWER 4 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1999-347867 [30] WPIDS
DNC C1999-102526
TI Use of androsterone derivatives for inhibiting DNA binding of AP-1 and airway smooth muscle proliferation.
DC B01
IN KENNEDY, T P
PA (CHAR-N) CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY; (CARO-N) CAROLINAS MEDICAL CENT; (CHAR-N) CHARLOTTE-MECKLENBURG HOSPITAL DBA CAROL

CYC 28
PI AU 9914693 A 19990401 (199930)* 58p A61K031-565
EP 934745 A1 19990811 (199936) EN A61K031-565
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
CA 2260584 A1 19990804 (200004) EN A61K031-565
JP 2000016939 A 20000118 (200014) 75p A61K031-566
ADT AU 9914693 A AU 1999-14693 19990202; EP 934745 A1 EP 1999-200310 19990203; CA 2260584 A1 CA 1999-2260584 19990202; JP 2000016939 A JP 1999-25737 19990203
PRAI US 1998-18782 19980204
IC ICM A61K031-565; A61K031-566
ICS **A61K009-12**; **A61K009-72**; A61P011-06; A61P011-08; A61P043-00
ICA C07J001-00
AB AU 9914693 A UPAB: 19990802
NOVELTY - Method for the treatment of inhibition of DNA binding of AP-1 and airway smooth muscle proliferation in an animal, comprising administering an effective amount of an androsterone derivative (I) or (II).
DETAILED DESCRIPTION - Method for the treatment of inhibition of DNA binding of AP-1 and airway smooth muscle proliferation in an animal, comprising administering an effective amount of an androsterone derivative of formula (I) and (II).
X = halo, OH, H, lower alkyl or lower alkoxy;
Y = H or OH; and
Z = lower alkyl or H.
ACTIVITY - Antiasthmatic; cystostatic.
MECHANISM OF ACTION - DNA binding of AP-1 inhibitor.
USE - (I) or (II) can be used to reduce the growth of airway smooth muscle, inhibit bronchoconstriction, inhibit asthma-related secretion of inflammatory cytokines by airway epithelium, inhibit acetylcholine mediated, vagal airways hyperreactivity in asthma, potentiating bronchodilator activity and reduces glucocorticoid insensitivity in asthma by inhibition of AP-1.
To study the effect of **DHEA** and 16 alpha -BrEA on activation of AP-1, a secondary response important in cellular growth and proliferation (Angel and Karin, (1991), supra), confluent monolayers of airway smooth muscle in 75 cm2 petri dishes were growth arrested for 24 hours in 0.5% FBS and DMEM and pretreated 2 hours with **DHEA** , 16 alpha -BrEA or DMSO vehicle. Cells were then stimulated with 10% FBS (fetal bovine serum) in DMEM for 6 hours, nuclear protein harvested, and electrophoretic mobility shift assays were performed to determine if treatment with **DHEA** and 16 alpha -BrEA impaired DNA binding of AP-1.
Dwg.0/22
FS CPI
FA AB; GI; DCN
MC CPI: B01-D02; B14-H01B; B14-K01A; B14-K01D; B14-L06

L96 ANSWER 5 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1999-216913 [19] WPIDS
DNC C1999-064004
TI New agent for promoting increase in content of hyaluronic acid in skin comprising **dehydroepiandrosterone** and derivatives is useful for preventing skin aging and scar formation.
DC B01
IN ISHIKAWA, Y; MATSUSHITA, H; NISHINA, H
PA (ADSK-N) INST ADVANCED SKIN RES INC; (ADSK-N) ADVANCED SKIN RES KENKYUSHO KK
CYC 26
PI EP 908183 A1 19990414 (199919)* EN 10p A61K031-565
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
JP 11193236 A 19990721 (199939) 4p A61K031-565
ADT EP 908183 A1 EP 1998-118921 19981007; JP 11193236 A JP 1998-286221

19981008
PRAI JP 1997-275870 19971008
IC ICM A61K031-565
ICS **A61K009-06**; A61K031-00
ICA C08B037-08
AB EP 908183 A UPAB: 19990518
NOVELTY - An agent for promoting an increase in the content of hyaluronic acid in skin is new and contains **dehydroepiandrosterone** (derivatives and/or salts) as an active agent.
ACTIVITY - Prevents skin aging and inhibits scar formation.
MECHANISM OF ACTION - Hyaluronic acid enhancer.
USE - The use of a **dehydroepiandrosterone** (derivatives and/or salts) is useful in a composition for promoting an increase in the hyaluronic acid content in skin for preventing skin aging or minimizing scar formation during healing of a skin injury (claimed).
ADVANTAGE - **Dehydroepiandrosterone** is effective at inhibiting scar formation during the healing of an injury to skin and unlike prior art agents e.g. retinoic acid and estrogens, the agent is not teratogenic and does not induce cardiovascular disorders and is therefore a safe drug. It has minimum side-effects and ameliorates the symptoms of aging.
DESCRIPTION OF DRAWING(S) - The drawing illustrates how the content of hyaluronic acid in skin increased when the **DHEA** of the invention and comparative drugs were applied to the aging skin of animals.
Dwg.1/2
FS CPI
FA AB; GI; DCN
MC CPI: B04-C02E; B14-N17

L96 ANSWER 6 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1999-036235 [04] WPIDS
DNC C1999-011060
TI Bio adhesive **tablets** for **trans-mucosal** drug delivery - containing lubricant and auxiliary in specific ratio and having surfaces grooves, giving high bio availability.
DC A96 B07
IN DITTGEN, M; GRAWE, D; HOFFMANN, H; SCHUHMACHER, J; TIMPE, C; ZIMMERMANN, H; SCHUMACHER, J
PA (JENP) JENAPHARM GMBH & CO KG; (JENP) JENAPHARM GMBH
CYC 27
PI DE 19734538 C1 19981224 (199904)* 8p A61K009-44 <--
EP 894495 A1 19990203 (199910) DE A61K009-00 <--
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
JP 11152221 A 19990608 (199933) 8p A61K009-20 <--
JP 3024756 B2 20000321 (200019) 7p A61K009-20 <--
US 6063404 A 20000516 (200031) A61K009-20 <--
ADT DE 19734538 C1 DE 1997-19734538 19970730; EP 894495 A1 EP 1998-250231 19980624; JP 11152221 A JP 1998-216325 19980730; JP 3024756 B2 JP 1998-216325 19980730; US 6063404 A US 1998-124577 19980729
FDT JP 3024756 B2 Previous Publ. JP 11152221
PRAI DE 1997-19734538 19970730
IC ICM **A61K009-00**; **A61K009-20**; **A61K009-44**
ICS A61K031-56; A61K047-30; A61K047-38
AB DE 19734538 C UPAB: 19990210
Novel bio-adhesive **tablets** contain at least one bio-adhesive auxiliary (I) and at least one lubricant (II). At least one surface of the **tablet** has concentric or parallel, linear and/or curved indentations. The ratio of (II) to (I) is 1: 1300-1.
Also claimed is the preparation of the **tablets** (no procedure specified).
USE - The **tablets** adhere to mucosa (e.g. buccal, gastro-intestinal, peri-ocular, nasal, vaginal or rectal mucosa) and provide local or systemic drug release. The **tablets** are specifically medicaments containing an antirheumatic, analgesic, anti-parkinson, beta -blocker, sexual hormone, contraceptive,

cardiovascular, sleep and hypophyseal hormone, antidiabetic, immuno-therapeutic or anticoagulant drug (all claimed). Adminstration is preferably oral, vaginal or rectal.

ADVANTAGE - The above ratio of (I) to (II) allows **tabletting** while simultaneously providing bio-adhesive properties, despite the antagonistic actions of (I) and (II). The **tablets** (or their decomposition products) do not inhibit the penetration of the drug into the mucosa by swelling. The drug is resorbed over an increased area of the target organ, and is almost completely released. Drug penetration into the mucosa is promoted, bio-availability is high and there are no undesirable reciprocal actions with the biological tissue. The **tablets** are solid, and the drug remains stable and protected before microbial attack.

Dwg.1/9

FS CPI
FA AB; GI; DCN
MC CPI: A12-V01; B04-C02A; B04-C03B; **B12-M11B**

L96 ANSWER 7 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1998-568475 [48] WPIDS
DNC C1998-170872
TI Pharmaceutical composition of an alkanoyl L-carnitine and **dehydro -epiandrosterone** or its sulphate - for promoting bone callus formation and fracture healing.
DC B01 B05
IN CAVAZZA, C
PA (SIGT) SIGMA-TAU IND FARM RIUNITE SPA
CYC 83
PI WO 9846233 A1 19981022 (199848)* EN 15p A61K031-565
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
AU 9870774 A 19981111 (199912) A61K031-565
EP 977576 A1 20000209 (200012) EN A61K031-565
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
BR 9809762 A 20000620 (200038) A61K031-565
ADT WO 9846233 A1 WO 1998-IT76 19980403; AU 9870774 A AU 1998-70774 19980403; EP 977576 A1 EP 1998-917594 19980403, WO 1998-IT76 19980403; BR 9809762 A BR 1998-9762 19980403, WO 1998-IT76 19980403
FDT AU 9870774 A Based on WO 9846233; EP 977576 A1 Based on WO 9846233; BR 9809762 A Based on WO 9846233
PRAI IT 1997-RM217 19970416
IC ICM A61K031-565
AB WO 9846233 A UPAB: 19981203
A pharmaceutical composition comprises (i) an alkanoyl L-carnitine where alkanoyl is 2-8C straight or branched, or a salt of such, and (ii) **dehydroepiandrosterone** or its sulphate, and one or more excipients.

USE - The composition is used for promoting the formation of bone callus and for the healing of fractures. It may be administered orally, rectally, parenterally or transdermally, and may take the form eg. of a solid, semisolid, liquid, semiliquid, powder, granule or liposome, presented as a **tablet**, capsule, granule, powder or ampoule.

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B01-D02; B10-A22; B14-N01; B14-N17B

L96 ANSWER 8 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1998-522303 [45] WPIDS
DNC C1998-156950
TI Solid oral controlled release dosage form preparation - by combining three or four compressed **tablets** with different, pre-designed release

properties, e.g. in pulsed release capsule.
DC B07
IN DITTGEN, M; EICHARDT, A; FRICKE, S; GERECKE, H; TIMPE, C; DITTGEN, M H
PA (JENP) JENAPHARM GMBH & CO KG
CYC 82
PI DE 19718012 C1 19981008 (199845)* 13p A61K009-52 <--
WO 9848782 A1 19981105 (199850) DE A61K009-48 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW
AU 9880099 A 19981124 (199914) A61K009-48 <--
EP 979069 A1 20000216 (200014) DE A61K009-48 <--
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
CZ 9903804 A3 20000412 (200026) A61K009-22 <--
BR 9809328 A 20000704 (200040) A61K009-48 <--
US 6117450 A 20000912 (200046) A61K009-22 <--
ADT DE 19718012 C1 DE 1997-19718012 19970429; WO 9848782 A1 WO 1998-DE979 19980407; AU 9880099 A AU 1998-80099 19980407; EP 979069 A1 EP 1998-928152 19980407, WO 1998-DE979 19980407; CZ 9903804 A3 WO 1998-DE979 19980407, CZ 1999-3804 19980407; BR 9809328 A BR 1998-9328 19980407, WO 1998-DE979 19980407; US 6117450 A US 1998-65863 19980424
FDT AU 9880099 A Based on WO 9848782; EP 979069 A1 Based on WO 9848782; CZ 9903804 A3 Based on WO 9848782; BR 9809328 A Based on WO 9848782
PRAI DE 1997-19718012 19970429
IC ICM **A61K009-22; A61K009-48; A61K009-52**
ICS **A61K009-26; A61K009-28;** A61K031-56
AB DE 19718012 C UPAB: 19981111
Preparation of an orally administered solid dosage form (specifically a capsule) for controlled release of active agent (I) involves combining at least three out of four compressed **tablets** (A)-(D) (variable in nature and number) containing at least one (I) (obtained by mixing with additives and/or carriers, granulating, **tabletting** and coating), to provide the desired (I) release profile, e.g. retarded, constant level or special 'rhythm' (pulsed) release. **Tablet** (A) releases at least 75% of its (I) content within 45 mins. **Tablet** (B) releases 100% of its (I) content at the earliest after 3 hrs., with a zero-order release profile obtained using a hydrophilic-lipophilic matrix **tablets** or diffusion-controlled lacquer coating. **Tablet** (C) releases at least 75% of its (I) content within 45 mins. at pH 6-7.5, and is an analogue of (A) with a gastric juice resistant coating. **Tablet** (D) releases 100% of its (I) content at the earliest after 3 hrs. at pH 6-7.5, with a zero-order release profile obtained using gastric juice-resistant matrix **tablets** or combinations of gastric juice-resistant and diffusion controlled lacquer coatings.
USE - The dosage forms are especially useful for administration of: natural body hormones which have a short in vivo half-life (e.g. progesterone, testosterone, **dehydro-epiandrosterone**, oestriol or oestradiol) or which have levels following a circadian rhythm (e.g. prednisone, prednisolone, cortexone, corticosterone, aldosterone or melatonin); analogues or inhibitors of such hormones, e.g. antidiabetics, glucocorticoids, mineralocorticoids or antihistamines; or combinations of the above drugs.
ADVANTAGE - Solid dosage forms with a variety of controlled release profiles (including pulsed release) can be prepared using a minimum of apparatus and time. By varying the nature and number of components (A)-(D) twelve possible release profile possibilities are provided.
Dwg.0/4
FS CPI
FA AB; DCN
MC CPI: B01-A02; B01-B01; B01-B02; B01-C04; B01-C05; B12-M10; **B12-M11**

L96 ANSWER 9 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1998-427685 [36] WPIDS
DNC C1998-128957

TI Composition for transdermal steroid administration - uses di ethylene glycol ether and sorbitan ester as absorption promoter.
DC A96 B01 B05 B07
IN CHOI, J K; CHOI, M S; MOON, C; RYOO, J P; CHOI, J; CHOI, M; RYOO, J; CHOI, J G
PA (GLDS) LG CHEM LTD
CYC 28
PI WO 9832465 A1 19980730 (199836)* EN 26p A61K047-14
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU BR CA CN JP MX RU SG US
AU 9858820 A 19980818 (199851) A61K047-14
KR 98066583 A 19981015 (199950) A61K009-70 <--
BR 9807009 A 20000314 (200027) A61K047-14
CN 1244806 A 20000216 (200027) A61K047-14
EP 1001812 A1 20000524 (200030) EN A61K047-14
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
JP 2000508349 W 20000704 (200037) 20p A61K047-14
ADT WO 9832465 A1 WO 1998-KR13 19980123; AU 9858820 A AU 1998-58820 19980123; KR 98066583 A KR 1997-2233 19970127; BR 9807009 A BR 1998-7009 19980123, WO 1998-KR13 19980123; CN 1244806 A CN 1998-802010 19980123; EP 1001812 A1 EP 1998-902269 19980123, WO 1998-KR13 19980123; JP 2000508349 W JP 1998-531848 19980123, WO 1998-KR13 19980123
FDT AU 9858820 A Based on WO 9832465; BR 9807009 A Based on WO 9832465; EP 1001812 A1 Based on WO 9832465; JP 2000508349 W Based on WO 9832465
PRAI KR 1997-2233 19970127
IC ICM **A61K009-70**; A61K047-14
ICS A61K031-56; A61K031-565; A61K031-568; A61K047-10
AB WO 9832465 A UPAB: 19980911
A composition for the transdermal administration of a steroid drug comprises a therapeutically effective amount of the drug, an absorption promoter consisting of a diethylene glycol ether and a sorbitan ester, and an adhesive matrix. Also claimed is a total formulation for the administration comprising a protective backing layer, a drug reservoir layer containing the defined composition, which is placed on the protective backing layer, one side of which is laminated on the protective backing layer, and a removable peel layer attached to the other side of the drug reservoir layer. Such a formulation may optionally comprise a supplementary adhesive layer.
USE - Exemplary drugs are estrogens, progestogens and androgens and their mixtures, e.g. estradiol, ethynyl estradiol, estradiol ester, norethisterone and its acetate, medroxyprogesterone acetate, desogestrel, gestaten, levonorgestrel, testosterone and its propionate, enanthate and cypionate, methyl testosterone and **dehydroepiandrosterone**.
Dwg.1/5
FS CPI
FA AB; GI; DCN
MC CPI: A12-V01; A12-V03A; B01-A02; B07-A02; B10-E04C; B12-M02F

L96 ANSWER 10 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1998-289306 [26] WPIDS
DNC C1998-089642
TI Hormone replenishment method for improvement of life expectancy - comprises evaluation of blood levels of hGH and several other hormones, then establishing regime to achieve optimum levels.
DC B01 B04
IN CHEIN, E Y M
PA (CHEI-I) CHEIN E Y M; (CHEI-I) CHEIN E
CYC 5
PI GB 2320190 A 19980617 (199826)* 49p A61K038-27
JP 10298103 A 19981110 (199904) 69p A61K038-27
US 5855920 A 19990105 (199909) A61K035-55
KR 98064080 A 19981007 (199949) A61K038-22
CN 1233503 A 19991103 (200011)# A61K038-22
ADT GB 2320190 A GB 1997-15349 19970721; JP 10298103 A JP 1997-369889 19971215; US 5855920 A US 1996-766320 19961213; KR 98064080 A KR 1997-68149 19971212; CN 1233503 A CN 1998-101688 19980430

PRAI US 1996-766320 19961213; CN 1998-101688 19980430
IC ICM A61K035-55; A61K038-22
ICS A61K031-405; A61K031-56; A61K031-565; A61K035-26; A61K038-00
ICA **A61K009-08**; A61K038-27
ICI A61K031:40, A61K031:565, A61K031:57, A61K038:30, A61K038:32
AB GB 2320190 A UPAB: 19980701
A hormone replenishment method comprises : (a) determining that the level of human growth hormone (hGH) and at least two supplemental hormones selected from sex hormone, melatonin hormone, adrenal hormone, thyroid hormone and thymus hormone are below optimal levels; and (b) establishing a regime with suitable amounts of the deficient hormones to give optimal levels. Also claimed is a kit containing hGH and at least two of the above hormones.
USE - The method increases life expectancy and life span (claimed) by reversal and prevention of the symptoms of aging.
ADVANTAGE - Combined therapy avoids the side effects (fluid retention, carpal tunnel syndrome) which may be associated with previous methods of hGH administration, because the low dose-high frequency regime mimics the body's own release of hormones.
Dwg.0/8
FS CPI
FA AB; DCN
MC CPI: B01-A01; B01-A02; B01-C04; B01-C05; B01-D01; B01-D02; B04-B04D5; B04-H01; B04-J01; B04-J04; B04-J05; B11-C08E; B12-K04A; B14-D01; B14-E11

L96 ANSWER 11 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1998-230216 [20] WPIDS
DNC C1998-071831
TI Enhancing dissolution properties of dietary supplement compositions - by solubilising supplement with solubiliser and incorporating edible poly hydric alcohol.
DC B05 D13
IN GOLDMAN, R
PA (BIOS-N) BIOSYTES USA INC
CYC 68
PI WO 9803170 A1 19980129 (199820)* EN 21p A61K031-355
RW: AT BE CH DE DK ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN
AU 9740413 A 19980210 (199827) A61K031-355
EP 866697 A1 19980930 (199843) EN A61K031-355
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 6056971 A 20000502 (200029) A61K009-48 <--
ADT WO 9803170 A1 WO 1997-US12561 19970724; AU 9740413 A AU 1997-40413 19970724; EP 866697 A1 EP 1997-937985 19970724, WO 1997-US12561 19970724; US 6056971 A Provisional US 1996-22564 19960724, US 1997-899454 19970723
FDT AU 9740413 A Based on WO 9803170; EP 866697 A1 Based on WO 9803170
PRAI US 1996-22564 19960724; US 1997-899454 19970723
IC ICM **A61K009-48**; A61K031-355
AB WO 9803170 A UPAB: 19980520
Enhancing the dissolution properties of dietary supplements (DSs) comprises: (a) providing at least one DS; (b) solubilising the DS with a solubiliser; and (c) incorporating an edible polyhydric alcohol into the solubilised DS to give a solubilised DS with enhanced dissolution properties.
The DS is relatively water insoluble. It includes at least 1 vitamin and at least 1 mineral. It includes coenzyme-Q10 (ubiquinone), tumeric extract (curcuminoids), beta -carotene, mixed carotenoids complex, lutein, lycopene, tocotrienols, tocopherols (vitamin E), saw palmetto lipid extract, exhinacea extract, hawthorn berry extract, ginseng extract, lipoic acid (thiotic acid), ascorbyl palmitate, kava extract, St. John's wort extract (hypericum), dihydroepiandrosterone, quercetin extract and/or indol-3-carbinol. The DS makes up 1-50 wt.% of the final composition.

The solubiliser is selected from Span type materials and Tween type materials. The solubiliser makes up 2-90 wt.% of the final composition.

The edible polyhydric alcohol is propylene glycol and/or glycerol. The alcohol makes up 2-50 wt.% of the final product.

The final product may be incorporated into a gelatin capsule or absorbed onto a starch and compressed into a **tablet**.

USE - The DS may be used for many purposes e.g. to treat congestive heart failure, other cardiac problems or to treat depression.

ADVANTAGE - The supplement dissolves readily in the digestive tract and thus shows improved bioavailability.

Dwg.0/3

FS CPI
FA AB; DCN
MC CPI: B04-A10F; B04-C03C; B10-E02; B10-E04C; **B12-M11C**; B14-F01B; B14-J01A1; D03-H01T2

L96 ANSWER 12 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1997-244729 [22] WPIDS
DNC C1997-079225
TI Liposomes containing 5beta-steroid or related compound in its lipid component - for treating obesity, diabetes, hypercorticoidism and bone marrow suppression, providing better delivery to liver.
DC B01
IN FINEMAN, E L; RUBINFELD, J
PA (SUPE-N) SUPERGEN INC
CYC 23
PI WO 9713500 A2 19970417 (199722)* EN 27p A61K009-127 <--
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: CA CN HU IL JP
WO 9713500 A3 19970529 (199737) A61K009-127 <--
EP 801557 A1 19971022 (199747) EN A61K009-127 <--
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
JP 10508322 W 19980818 (199843) 29p A61K031-565
HU 9801834 A2 19990301 (199916) A61K009-127 <--
ADT WO 9713500 A2 WO 1996-US15507 19960927; WO 9713500 A3 WO 1996-US15507 19960927; EP 801557 A1 EP 1996-933929 19960927, WO 1996-US15507 19960927; JP 10508322 W WO 1996-US15507 19960927, JP 1997-515066 19960927; HU 9801834 A2 WO 1996-US15507 19960927, HU 1998-1834 19960927
FDT EP 801557 A1 Based on WO 9713500; JP 10508322 W Based on WO 9713500; HU 9801834 A2 Based on WO 9713500
PRAI US 1995-542083 19951012
REP 1.Jnl.Ref; DE 3626421; EP 139554; WO 9404155
IC ICM **A61K009-127**; A61K031-565
ICS A61K038-00
AB WO 9713500 A UPAB: 19970530
Liposomes in which the lipid component contains sufficient of a 5 beta -steroid (I) or 3 beta -hydroxyandrost-5-en-17-one (**DHEA**) to treat obesity, diabetes and/or hypercorticoidism are new.Also new are liposomes containing the derivative (II) of a dicarboxylic acid (III) in which one carboxy is bonded via an ester link to (I) while the other carboxy group is free or in salt form.

USE - The liposomes can also be used to treat bone marrow suppression disorders.

ADVANTAGE - These liposomes improve delivery of (I) or **DHEA** (known as anti-obesity etc. agents) to the liver; compare oral administration where only 5-15% of the steroid enters the blood. This allows the dose, and thus cost, to be reduced.When the liposomes include a protein or peptide with anti-obesity activity, the blood levels of this are also increased. (I) or their derivatives can be used as a structural component in the liposomes, reducing the need for other steroid and/or lipid materials.

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B01-C09; B04-B01B; B04-C01; B04-N02; B14-G01; B14-G03

L96 ANSWER 13 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1997-065285 [06] WPIDS
DNC C1997-021473
TI Formulation for inducing sustained, regional local anaesthesia - comprises substrate of local anaesthetic and biocompatible, biodegradable, controlled-release material and non-toxic, augmenting agent.
DC A96 B05 B07
IN BURCH, R M; CHASIN, M; GOLDENHEIM, P; SACKLER, R; TIGNER, J
PA (EURO-N) EUROCELTIQUE SA
CYC 72
PI WO 9641616 A1 19961227 (199706)* EN 53p A61K009-14 <--
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG
W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN
AU 9662816 A 19970109 (199717) A61K009-14 <--
NO 9700589 A 19970408 (199725) A61K031-445
FI 9700522 A 19970407 (199727) A61K000-00
EP 778768 A1 19970618 (199729) EN A61K009-14 <--
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
NZ 311474 A 19970922 (199745) A61K009-14 <--
JP 10502673 W 19980310 (199820) 46p A61K009-14 <--
KR 97704424 A 19970906 (199839) A61K009-14 <--
HU 9700322 A2 19980628 (199840) A61K009-14 <--
MX 9700850 A1 19970901 (199850) A61K009-14 <--
JP 2897964 B2 19990531 (199927) 21p A61K009-14 <--
AU 706541 B 19990617 (199935) A61K009-14 <--
US 5942241 A 19990824 (199941) A61K009-52 <--
ADT WO 9641616 A1 WO 1996-US10439 19960607; AU 9662816 A AU 1996-62816 19960607; NO 9700589 A WO 1996-US10439 19960607, NO 1997-589 19970207; FI 9700522 A WO 1996-US10439 19960607, FI 1997-522 19970207; EP 778768 A1 EP 1996-921643 19960607, WO 1996-US10439 19960607; NZ 311474 A NZ 1996-311474 19960607, WO 1996-US10439 19960607; JP 10502673 W WO 1996-US10439 19960607, JP 1997-503389 19960607; KR 97704424 A WO 1996-US10439 19960607, KR 1997-700851 19970206; HU 9700322 A2 WO 1996-US10439 19960607, HU 1997-322 19960607; MX 9700850 A1 MX 1997-850 19970203; JP 2897964 B2 WO 1996-US10439 19960607, JP 1997-503389 19960607; AU 706541 B AU 1996-62816 19960607; US 5942241 A Provisional US 1995-105 19950609, WO 1996-US10439 19960607, US 1997-793861 19970616
FDT AU 9662816 A Based on WO 9641616; EP 778768 A1 Based on WO 9641616; JP 10502673 W Based on WO 9641616; KR 97704424 A Based on WO 9641616; HU 9700322 A2 Based on WO 9641616; JP 2897964 B2 Previous Publ. JP 10502673, Based on WO 9641616; AU 706541 B Previous Publ. AU 9662816, Based on WO 9641616; US 5942241 A Based on WO 9641616
PRAI US 1995-105 19950609; US 1997-793861 19970616
REP 1.Jnl.Ref; WO 9405265
IC ICM A61K000-00; **A61K009-14**; **A61K009-52**
ICS **A61K009-107**; A61K031-19; A61K031-24; A61K031-505; A61K031-56; A61K031-715; A61K047-34; A61K047-42
ICA A61K031-135; A61K031-415; A61K031-435; A61K031-44; A61K031-445; A61K031-54; A61K031-55; A61K031-57
AB WO 9641616 A UPAB: 19981028
Formulation for inducing sustained, regional local anaesthesia comprises: (a) a substrate comprising a local anaesthetic and an effective amt. of a biocompatible, biodegradable, controlled-release material prolonging the release of the local anaesthetic to give a reversible local anaesthesia when implanted or injected in a patient; and (b) a non-toxic, augmenting agent effective to prolong the duration of the local anaesthesia for a period longer than that obtd. from the substrate without the augmenting agent, where the augmenting agent is not a glucocorticosteroid agent.

USE - The compsns. are biodegradable, controlled-release formulations for the admin. of locally active drugs, i.e. local anaesthetics and can be used to provide post-operative-pain control.

ADVANTAGE - The compsns. provide augmented potency and duration of local anaesthetics.

Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: A12-V01; B04-C03D; B07-D05; B11-C04B; B12-M10A; B14-C08

L96 ANSWER 14 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1996-343351 [35] WPIDS
DNC C1996-109052
TI Use of **dehydro-epi-androsterone** sulphate in topical treatment of skin ageing - effective e.g. against wrinkles and cutaneous slackness.
DC B01 D21
IN BRETON, L; DE, LACHARRIERE O
PA (OREA) L'OREAL SA; (OREA) SOC L'OREAL SA
CYC 7
PI EP 723775 A1 19960731 (199635)* FR 5p A61K007-48
R: DE ES FR GB IT
FR 2729854 A1 19960802 (199638) 7p A61K007-48
JP 08231342 A 19960910 (199646) 4p A61K007-00
EP 723775 B1 19971210 (199803) FR 6p A61K007-48
R: DE ES FR GB IT
DE 69600115 E 19980122 (199809) A61K007-48
ES 2113219 T3 19980416 (199822) A61K007-48
US 5900242 A 19990504 (199925) A61K009-48 <--
US 5989568 A 19991123 (200002) A61K007-48
JP 2000001415 A 20000107 (200012) 4p A61K007-00
ADT EP 723775 A1 EP 1996-400049 19960109; FR 2729854 A1 FR 1995-899 19950126; JP 08231342 A JP 1996-10466 19960124; EP 723775 B1 EP 1996-400049 19960109; DE 69600115 E DE 1996-600115 19960109, EP 1996-400049 19960109; ES 2113219 T3 EP 1996-400049 19960109; US 5900242 A Div ex US 1996-592175 19960126, US 1997-899880 19970724; US 5989568 A US 1996-592175 19960126; JP 2000001415 A Div ex JP 1996-10466 19960124, JP 1999-160157 19960124
FDT DE 69600115 E Based on EP 723775; ES 2113219 T3 Based on EP 723775
PRAI FR 1995-899 19950126
REP 1.Jnl.Ref; EP 189738; FR 2405068; JP 60161912; WO 9416709
IC ICM A61K007-00; A61K007-48; **A61K009-48**
ICA C07J001-00
AB EP 723775 A UPAB: 19960905
Use of **dehydro-epi-androsterone** sulphate (I) in a topical compsn. for treating wrinkles and fine lines, combatting cutaneous and/or subcutaneous slackness and/or reviving the appearance of the skin is new. Also claimed is the use of (I) in conjunction with at least one active ingredient selected from alpha- or beta-hydroxyacids, alpha- or beta-ketoacids, retinoids, benzoyl peroxide and anti-free radical agents and at least one natural or synthetic hormone selected from oestrogens, progestatives and androgens.

USE - The compsn. is useful in treating slackness and/or break-up of the cutaneous micro-relief, treating cutaneous and/or subcutaneous looseness, making the skin firm and/or toning the texture of the skin (all claimed). (I) is applied at a concn. of 0.00001-5 (pref. 0.001-0.5) wt.% in conventional topical formulations such as solns., lotions, gels, emulsions or creams.

ADVANTAGE - (I) is effective against morphological disorders associated with endogenous and/or exogenous ageing of the skin, leading to a younger-looking skin.

Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B01-D02; B14-N17; B14-R01; D08-B09A
ABEQ EP 723775 B UPAB: 19980119
Use of **dehydro-epi-androsterone** sulphate (I) in a topical compsn. for treating wrinkles and fine lines, combatting cutaneous and/or subcutaneous slackness and/or reviving the appearance of the skin is new. Also claimed is the use of (I) in conjunction with at least one active ingredient selected from alpha - or beta -hydroxyacids, alpha - or beta -ketoacids, retinoids, benzoyl peroxide and anti-free

radical agents and at least one natural or synthetic hormone selected from oestrogens, progestatives and androgens.

USE - The compsn. is useful in treating slackness and/or break-up of the cutaneous micro-relief, treating cutaneous and/or subcutaneous looseness, making the skin firm and/or toning the texture of the skin (all claimed). (I) is applied at a concn. of 0.00001-5 (pref. 0.001-0.5) wt.% in conventional topical formulations such as solns., lotions, gels, emulsions or creams.

ADVANTAGE - (I) is effective against morphological disorders associated with endogenous and/or exogenous ageing of the skin, leading to a younger-looking skin.

Dwg.0/0

L96 ANSWER 15 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1996-139448 [14] WPIDS
DNC C1996-043783
TI Treatment of myotonic dystrophy e.g. in muscular dystrophy - using **dehydro-epiandrosterone** sulphate or its salt, orally or by injection.
DC B01
IN ENDO, T; OHSAWA, N; SUGINO, M
PA (KANE) KANEBO LTD; (ENDO-I) ENDO T; (OSAW-I) OSAWA N; (SUGI-I) SUGINO S
CYC 21
PI WO 9604917 A1 19960222 (199614)* JA 18p A61K031-565
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: CN KR US
JP 08048630 A 19960220 (199617) 5p A61K031-565
EP 776663 A1 19970604 (199727) EN A61K031-565
R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
JP 2698865 B2 19980119 (199808) 4p A61K031-565
EP 776663 A4 19971029 (199840) A61K031-565
US 5834451 A 19981110 (199901) A61K031-56
ADT WO 9604917 A1 WO 1995-JP1561 19950807; JP 08048630 A JP 1994-205939 19940808; EP 776663 A1 EP 1995-927977 19950807, WO 1995-JP1561 19950807; JP 2698865 B2 JP 1994-205939 19940808; EP 776663 A4 EP 1995-927977 19950807; US 5834451 A WO 1995-JP1561 19950807, US 1997-776888 19970415
FDT EP 776663 A1 Based on WO 9604917; JP 2698865 B2 Previous Publ. JP 08048630; US 5834451 A Based on WO 9604917
PRAI JP 1994-205939 19940808
REP DE 2540131; FR 2317933; GB 8809833; JP 5212933; JP 6183979; JP 6299328; JP 63267722; US 4005200; 1.Jnl.Ref
IC ICM A61K031-56; A61K031-565
ICS **A61K009-08**; **A61K009-48**; C07J001-00
AB WO 9604917 A UPAB: 19981021
An agent for treating myotonic dystrophy disease and myotonia contains **dehydroepiandrosterone** sulphate (I) or its salt, pref. the sodium salt (IA).

USE - The agent is used to treat muscular dystrophy and other conditions with myotonia, including adynamia and amyotrophy. Admin. is oral or by injection. Dose is 10-21000 mg/day orally or by other routes, in various formulations.

ADVANTAGE - The agent is safe and effective in resolving muscular contractions, so improving the activities of daily living (ADL).

Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B01-D02; B14-S05

L96 ANSWER 16 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1995-224140 [29] WPIDS
DNC C1995-103096
TI New liposomes, esp. for drug delivery - having internal aq. phase contg. complex of active cpd. with receptor, e.g. for rendering hydrophobic drugs hydrophilic.
DC B04 B07
IN GREGORIADIS, G; MCCORMACK, B

PA (UNLO) UNIV LONDON SCHOOL PHARMACY
CYC 19
PI WO 9515746 A1 19950615 (199529)* EN 45p A61K009-127 <--
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: CA GB JP US
ADT WO 9515746 A1 WO 1994-GB2702 19941209
PRAI GB 1993-25277 19931210; GB 1993-25276 19931210
REP 01Jnl.Ref; EP 261719; JP 04351950; WO 9311757; WO 9423697
IC ICM **A61K009-127**
ICS A61K047-48
AB WO 9515746 A UPAB: 19951122
Novel liposomes (I) contain at least one complex (II) in the aq. phase inside the liposome. (II) comprises at least one molecule (III) non-covalently bound to at least one receptor (IV).
Also claimed is the prepn. of a complex (II') by: (a) contacting an annular receptor molecule (II') with a guest molecule (III') in soln. to form (II'); and (b) subjecting a soln. of (II') to gel permeation chromatography to separate (II') from non-complexed (III')
USE - (I) are esp. used as a drug delivery system (claimed). (III)/(III') is specifically a pharmaceutical vaccine, genetic material, enzyme, hormone, vitamin, metal chelator, antitumour agent or antimicrobial agent (all claimed). Prepns. for topical admin. or intravenous injection contg. (I) are claimed. Typical (III) (not specified in the claims) are morphine, indomethacin, naproxen, ketoprofen, tin etiopurpurin, pilocarpine, hydrocortisone, oestrogen, progesterone, prostaglandins, cholesterol, **dehydroepiandrosterone**, retinoic acid, retinol, chlorambucil, dexamethasone, beta-tocopherol, vitamin D or E, mephalon and vincristine. Liposomes are also useful in cosmetic applications.
ADVANTAGE - Bonding of (III) to (IV) can modify interactions of (III) with other components of (I), esp. by modifying the solubility of (III) and/or the interaction of (III) with the lipid bilayer. The tendency of (III) to escape from (I) may be reduced by bonding with (V), or hydrophobic (III) may be converted into hydrophilic (II). Solubilisation of hydrophobic (III) in the aq. phase of (I) may provide the benefit of liposome delivery (e.g. increased half-life and direction to specific body locations) for hydrophobic as well as hydrophilic drugs. Amt. of hydrophobic (III) in (I) can be increased. Leakage of small molecules (III) from (I) is reduced. If (IV) is cyclodextrin (CD) (or deriv.), use of liposomes reduces elimination of CD complexes by the kidneys and the nephrotoxicity problems of CD (cf. use of CD complexes alone). Problems of competition with other biomolecules, premature drug release and cell membrane solubilisation are also eliminated.
Dwg.0/1
FS CPI
FA AB; DCN
MC CPI: B03-H; B04-B01B; B04-E01; B04-J01; B04-K01; B04-L01; B05-B01P; **B12-M11E**; B14-A01; B14-H01B

L96 ANSWER 17 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1995-177489 [23] WPIDS
CR 1992-032702 [04]; 1993-151674 [18]; 1994-025355 [03]; 1995-381886 [49]; 1997-340977 [31]
DNC C1995-082225
TI Enhancement of protective immune response - by admin. of de hydro-epi-adrosterone.
DC B01 C03
IN LORIA, R M; REGELSON, W
PA (UYVI-N) UNIV VIRGINIA COMMONWEALTH
CYC 1
PI US 5407684 A 19950418 (199523)* 7p A23K001-165
ADT US 5407684 A CIP of US 1988-291969 19881230, US 1991-733198 19910719
FDT US 5407684 A CIP of US 5077284
PRAI US 1991-733198 19910719; US 1988-291969 19881230
IC ICM A23K001-165
ICS A01N045-00; **A61K009-08**; A61K031-565

AB US 5407684 A UPAB: 19970806
Method for enhancing the protective immune response of a mammal comprises admin. of **dehydroepiandrosterone** (**DHEA**) at a dose of 1-1000 mg./day.
Also claimed is a method for enhancing the protective immune response of a fish or bird by admin. of a compsn. as above.
Also claimed are: (1) a compsn. comprising fish or bird food or water contg. **DHEA**; and (2) a compsn. comprising **DHEA** and a vaccine in a carrier.
USE - The methods may be used to protect humans and other animals from side effects of ratio- or chemotherapy (e.g. hair loss) and from infections, e.g. by viruses such as herpes simplex or HIV, esp. in humans suffering from anemia, burns or diabetes or in form animals (e.g. during transport).
Dwg.0/4
FS CPI
FA AB; DCN
MC CPI: B01-D02; C01-D02; B14-A02; C14-A02; B14-F03; C14-F03; B14-G01; C14-G01; B14-N17A; C14-N17A; B14-R02; C14-R02; B14-S11; C14-S11

L96 ANSWER 18 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1995-161113 [21] WPIDS
DNC C1995-074695
TI Treatment of mild depression in mature humans - by admin. of **dehydro-epi-androsterone**.
DC B01
IN MORALES, A J; YEN, S S C
PA (RERE-N) RES DEV FOUND; (YENS-I) YEN S S C; (REDE-N) RES DEV FOUND
CYC 23
PI US 5407927 A 19950418 (199521)* 10p A61K031-56
EP 728483 A1 19960828 (199639)# EN 15p A61K031-565
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
AU 9512349 A 19960829 (199643)# A61K031-565
ZA 9501369 A 19960925 (199643)# 21p A61K000-00
FI 9500794 A 19960822 (199646)# A61K031-565
JP 08245395 A 19960924 (199648)# 7p A61K031-565
CA 2143064 A 19960822 (199650)# A61K031-565
ADT US 5407927 A US 1993-49729 19930416; EP 728483 A1 EP 1995-301102 19950221; AU 9512349 A AU 1995-12349 19950220; ZA 9501369 A ZA 1995-1369 19950220; FI 9500794 A FI 1995-794 19950221; JP 08245395 A JP 1995-40271 19950228; CA 2143064 A CA 1995-2143064 19950221
PRAI US 1993-49729 19930416; EP 1995-301102 19950221; AU 1995-12349 19950220; ZA 1995-1369 19950220; FI 1995-794 19950221; JP 1995-40271 19950228; CA 1995-2143064 19950221
IC ICM A61K000-00; A61K031-56; A61K031-565
ICS **A61K009-08**; **A61K009-20**; A61K031-595
ICA C07J013-00
AB US 5407927 A UPAB: 19950904
Method for increasing endogenous levels of insulin-like growth factor (IGF-I) in mature humans who are 40-80 years old and are in need of treatment of mild depression comprises admin. of **dehydroepiandrosterone** (**DHEA**) at a daily dose of 15-150 mg for more than 7 days. Also claimed is a method for treating mild depression in mature humans (aged 40-80), comprising admin. of **DHEA** at a daily dose of 15-150mg.
Dwg.0/5
FS CPI
FA AB; DCN
MC CPI: B01-D02; B14-J01A1

L96 ANSWER 19 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1995-098560 [13] WPIDS
DNC C1995-044839
TI Sustained release oral medicaments comprising carnitine - for treatment of e.g. osteoporosis without gastrointestinal irritation.
DC B05

IN GULBRANDSEN, C E; SHUG, A L
PA (GULB-I) GULBRANDSEN C E; (SHUG-I) SHUG A L
CYC 17
PI WO 9505168 A1 19950223 (199513)* EN 25p A61K031-205
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: CA
ADT WO 9505168 A1 WO 1994-US9332 19940819
PRAI US 1993-109159 19930819
REP US 4681755; US 5028664; US 5240961; US 5271946; US 5288505
IC ICM A61K031-205
ICS **A61K009-56; A61K009-58**
AB WO 9505168 A UPAB: 19950404
The following are claimed: (A) sustained release oral medicament for admin. to human beings, comprising (a) a unitary dosage amt. of carnitine (I), (b) a means for slowly releasing (I) from the medicament upon exposure of it to gastrointestinal fluid, and (c) a pharmaceutical excipient. (B) treatment and prevention of osteoprosis, comprising orally administering daily, in a sustained release formulation, (I) and **dehydroepiandrosterone**-sulphate along with an excipient.
USE - Compsn. (A) may be used for treatment of carnitine responsive disorders such as osteoporosis, severe muscle weakness, liver dysfunction, hypoglycaemia or cardiomyopathy.
ADVANTAGE - The compsn. does not cause adverse GI symptoms such as diarrhoea.
Dwg.1/3
FS CPI
FA AB; GI; DCN
MC CPI: B01-D02; B10-A22; B12-M10A; B14-F01; B14-J05; B14-N01; B14-N12

L96 ANSWER 20 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1994-263760 [32] WPIDS
DNC C1994-120651
TI Treating decreased sec. steroid secretion from adrenal(s) - using **de hydro-epi androsterone** or deriv., e.g. for treating menopausal symptoms or uterine cancer.
DC B01
IN LABRIE, F
PA (ENDO-N) ENDORECHERCHE INC
CYC 47
PI WO 9416709 A2 19940804 (199432)* EN 71p A61K031-57
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE
W: AT AU BB BG BR BY CA CH CN CZ DE ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA VN
AU 9453884 A 19940728 (199434) C07J043-00
AU 9458557 A 19940815 (199444) A61K031-57
NO 9502417 A 19950616 (199537) A61K031-56
FI 9503017 A 19950619 (199538) A61K000-00
ZA 9400372 A 19950927 (199544) 61p C07J000-00
EP 680327 A1 19951108 (199549) EN A61K031-57
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
CZ 9501565 A3 19951213 (199606) A61K031-57
WO 9416709 A3 19941124 (199610) A61K031-57
HU 73241 T 19960729 (199643) A61K031-565
JP 08505629 W 19960618 (199648) 86p A61K031-565
NZ 250712 A 19961126 (199701) A61K031-565
SK 9500779 A3 19970409 (199727) A61K031-57
CN 1116823 A 19960214 (199742) C07J017-00
AU 686120 B 19980205 (199813) C07J043-00
US 5728688 A 19980317 (199818) 16p A61K031-56
US 5776923 A 19980707 (199834) A61K031-58
US 5780460 A 19980714 (199835) A61K031-56
US 5798347 A 19980825 (199841) A61K031-56
US 5807849 A 19980915 (199844) A61K031-56
US 5824671 A 19981020 (199849) A61K031-56
US 5837700 A 19981117 (199902) A61K031-56
US 5843932 A 19981201 (199904) A61K031-56

US 5854229 A 19981229 (199908) A61K031-56
US 5872114 A 19990216 (199914) A61K031-56
US 5922700 A 19990713 (199934) A61K031-56
US 5948434 A 19990907 (199943) A61F013-00
US 5955455 A 19990921 (199945) A61K031-56

ADT WO 9416709 A2 WO 1994-CA22 19940119; AU 9453884 A AU 1994-53884 19940119; AU 9458557 A AU 1994-58557 19940119; NO 9502417 A WO 1994-CA22 19940119, NO 1995-2417 19950616; FI 9503017 A WO 1994-CA22 19940119, FI 1995-3017 19950619; ZA 9400372 A ZA 1994-372 19940119; EP 680327 A1 EP 1994-904546 19940119, WO 1994-CA22 19940119; CZ 9501565 A3 CZ 1995-1565 19940119; WO 9416709 A3 WO 1994-CA22 19940119; HU 73241 T WO 1994-CA22 19940119, HU 1995-1985 19940119; JP 08505629 W JP 1994-516509 19940119, WO 1994-CA22 19940119; NZ 250712 A NZ 1994-250712 19940119; SK 9500779 A3 WO 1994-CA22 19940119, SK 1995-779 19940119; CN 1116823 A CN 1994-190964 19940119; AU 686120 B AU 1994-53884 19940119; US 5728688 A Div ex US 1993-5619 19930119, US 1995-480591 19950607; US 5776923 A CIP of US 1993-5619 19930119, US 1994-180361 19940118; US 5780460 A Div ex US 1993-5619 19930119, US 1995-488392 19950607; US 5798347 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-477170 19950607; US 5807849 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-489909 19950613; US 5824671 A Div ex US 1993-5619 19930119, US 1995-480592 19950607; US 5837700 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-485750 19950607; US 5843932 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-473815 19950607; US 5854229 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-477173 19950607; US 5872114 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-481668 19950607; US 5922700 A Div ex US 1993-5619 19930119, US 1995-488391 19950607; US 5948434 A CIP of US 1993-5619 19930119, Div ex US 1994-180361 19940118, US 1995-485766 19950607; US 5955455 A Div ex US 1993-5619 19930119, Cont of US 1995-481909 19950607, US 1997-969197 19971113

FDT AU 9458557 A Based on WO 9416709; EP 680327 A1 Based on WO 9416709; HU 73241 T Based on WO 9416709; JP 08505629 W Based on WO 9416709; AU 686120 B Previous Publ. AU 9453884

PRAI US 1994-180361 19940118; US 1993-5619 19930119; US 1995-480591 19950607; US 1995-488392 19950607; US 1995-477170 19950607; US 1995-489909 19950613; US 1995-480592 19950607; US 1995-485750 19950607; US 1995-473815 19950607; US 1995-477173 19950607; US 1995-481668 19950607; US 1995-488391 19950607; US 1995-485766 19950607; US 1995-481909 19950607; US 1997-969197 19971113

REP No-SR.Pub; 4.Jnl.Ref; FR 1584879; GB 1246639; GB 2204490; US 4978532

IC ICM A61F013-00; A61K000-00; A61K031-56; A61K031-565; A61K031-57; A61K031-58; C07J000-00; C07J017-00; C07J043-00
ICS **A61K009-00**; **A61K009-70**; A61K047-28; A61M037-00; C07J001-00; C12P000-00

AB WO 9416709 A UPAB: 19940928
Prevention or treatment of menopause symptoms comprises admin. of at least one sex steroid precursor (I) selected from **dehydroepiandrosterone** (**DHEA**), **dehydroepiandrosterone** sulphate (**DHEA**-S) and cpds. (I') converted into **DHEA** or **DHEA**-S in vivo, opt. together with a carrier or diluent, as part of a combinational therapy with at least one additional agent (II) selected from oestrogens and progestins. Methods, all involving admin. of (I), are claimed for: preventing or treating vaginal atrophy; preventing or treating hypogonadism; preventing or treating diminished libido; treating reduced or imbalanced sex steroid concns. (using (I) by percutaneous or transmucosal admin. as a compsn. contg. at least 7 wt.% (I)), specifically for preventing or treating obesity, cardiovascular disease, atherosclerosis, breast or endometrial cancer, loss of muscle mass, diabetes, fatigue, loss of energy, connective tissue diseases; loss of memory or menopause symptoms; preventing or treating osteoporosis; preventing or treating urinary incontinence; contraception; preventing ovarian cancer; and preventing or treating uterine cancer. Various pharmaceutical compsns. etc. contg. (I) and opt. (II) are claimed; see 'Preferred Formulations' below. (I') include new cpds. of formula (I''); (i) X = H, RCO-, RCOOCHRa- or RbSO2-; R = H, alkyl, alkoxy, alkenyl,

alkynyl, aryl, furyl, alkenyloxy, alkynyloxy, aryloxy, furyloxy or corresp. halogenated analogues; Ra = H or 1-6C alkyl; Rb = OH (opt. as salt), Me, Ph or p-tolyl; Y = opt. substd. gp. of formula -NHCH2CH2Z-, forming a satd. 5-membered ring; Z = O or S; or (ii) X = RcCO- or RCOOCHR9-; Rc = alkyl, alkenyl, alkynyl, aryl or halogenated analogue; Y = O.

USE/ADVANTAGE - (I) are useful for treating or preventing a wide range of conditions (see above) related to decreased sex steroid secretion by the adrenals (e.g. due to ageing); or as contraceptives.

(I) are free of undesirable side-effects. They can be administered through the skin or mucosa, which is more efficient than oral admin. (as the liver is by-passed) and more convenient and less painful than injection, some lipophilic cpds. (I'') provide slow release of **DHEA**.

Dwg.0/9

FS CPI

FA AB; DCN

MC CPI: B01-D02; B14-E12; B14-F01; B14-F02; B14-F07; B14-H01B; B14-N01; B14-N07C; B14-N07D

ABEQ US 5728688 A UPAB: 19980507

Prevention or treatment of menopause symptoms comprises admin. of at least one sex steroid precursor (I) selected from **dehydroepiandrosterone** (**DHEA**), **dehydroepiandrosterone** sulphate (**DHEA**-S) and cpds. (I') converted into **DHEA** or **DHEA**-S in vivo, opt. together with a carrier or diluent, as part of a combinational therapy with at least one additional agent (II) selected from oestrogens and progestins. Methods, all involving admin. of (I), are claimed for: preventing or treating vaginal atrophy; preventing or treating hypogonadism; preventing or treating diminished libido; treating reduced or imbalanced sex steroid concns. (using (I) by percutaneous or transmucosal admin. as a compsn. contg. at least 7 wt.% (I)), specifically for preventing or treating obesity, cardiovascular disease, atherosclerosis, breast or endometrial cancer, loss of muscle mass, diabetes, fatigue, loss of energy, connective tissue diseases; loss of memory or menopause symptoms; preventing or treating osteoporosis; preventing or treating urinary incontinence; contraception; preventing ovarian cancer; and preventing or treating uterine cancer. Various pharmaceutical compsns. etc. contg. (I) and opt. (II) are claimed; see 'Preferred Formulations' below. (I') include new cpds. of formula (I''); (i) X = H, RCO-, RCOOCHRa- or RbSO2-; R = H, alkyl, alkoxy, alkenyl, alkynyl, aryl, furyl, alkenyloxy, alkynyloxy, aryloxy, furyloxy or corresp. halogenated analogues; Ra = H or 1-6C alkyl; Rb = OH (opt. as salt), Me, Ph or p-tolyl; Y = opt. substd. gp. of formula -NHCH2CH2Z-, forming a satd. 5-membered ring; Z = O or S; or (ii) X = RcCO- or RCOOCHR9-; Rc = alkyl, alkenyl, alkynyl, aryl or halogenated analogue; Y = O.

USE/ADVANTAGE - (I) are useful for treating or preventing a wide range of conditions (see above) related to decreased sex steroid secretion by the adrenals (e.g. due to ageing); or as contraceptives.

(I) are free of undesirable side-effects. They can be administered through the skin or mucosa, which is more efficient than oral admin. (as the liver is by-passed) and more convenient and less painful than injection, some lipophilic cpds. (I'') provide slow release of **DHEA**.

Dwg.0/0

L96 ANSWER 21 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

AN 1992-281666 [34] WPIDS

DNC C1992-125256

TI Vaginal suppository - contains **de hydro epiandrosterone** and hard fat with hydroxy carboxylic acid with specified hydroxyl gp. value.

DC B01 B07

PA (KANE) KANEBO LTD

CYC 1

PI JP 04193831 A 19920713 (199234)* 4p A61K031-565

ADT JP 04193831 A JP 1990-320282 19901122
PRAI JP 1990-320282 19901122
IC ICM A61K031-565
ICS **A61K009-02**; A61K047-12
AB JP 04193831 A UPAB: 19931025
Vaginal suppository contains **dehydroepiandrosterone** sulphates (DHAS) and hard fat with hydroxycarboxylic acid and hydroxyl group value of 50 or less.
Pref. hydroxycarboxylic acid is citric acid, L-tartaric acid and L-lactic acid. Hydroxycarboxylic acid is 2-6C aliphatic hydroxycarboxylic acid or 7-9C aromatic hydroxycarboxylic acid.
USE/ADVANTAGE - This suppository shows good vaginal absorption of DHAS. DHAS stimulates maturation of uterine cervix at later pregnancy period and increases sensitivity of the uterine muscle to oxytocin
FS CPI
FA AB; DCN
MC CPI: B01-D02; B10-C02; B10-C03; B10-C04D; B12-E09; B12-M08

L96 ANSWER 22 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1992-175206 [21] WPIDS
CR 1992-398023 [48]
DNC C1992-080458
TI Use of **dehydro-epiandrosterone** as platelet aggregation inhibitor - for treatment and prevention of atherosclerosis, angina, myocardial infarction, stroke and re-stenosis.
DC B01
IN EICH, D M; JESSE, R; NESTLER, J
PA (UYVI-N) VIRGINIA COMMONWEAL
CYC 1
PI US 5110810 A 19920505 (199221)* 11p
ADT US 5110810 A US 1991-652518 19910208
PRAI US 1991-652518 19910208
IC A61K031-56
AB US 5110810 A UPAB: 19931116
To reduce the rate of platelet aggregation in a patients blood plasma, **dehydroepiandrosterone** (I) is administered. A salt or ester of (I) may also be used, esp. the sulphate.
A therapeutic dose of the active cpd. is generally 100-2000mg, pref. about 300 mg/day orally. The active cpd. is pref. held within a solid binder or mixed with a liquid elixir.
USE - Reducing the rate of platelet aggregation can significantly reduce the incidence of morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. Atherosclerosis and angina may be treated or prevented by this method, which blocks thromboxane production
Dwg.0/7
FS CPI
FA AB; DCN
MC CPI: B01-D02; B12-F01B; B12-F02; B12-H03; B12-H04

L96 ANSWER 23 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1992-032702 [04] WPIDS
CR 1994-025355 [03]; 1995-177489 [23]; 1995-381886 [49]; 1997-340977 [31]
DNC C1992-014271
TI Use of steroid hormone **dehydro epiandrosterone** - to improve immune response and to protect against viral infections e.g. HIV, HSV-2, bacterial infections, etc..
DC B01 C03
IN LORIA, R M; REGELSON, W
PA (LORI-I) LORIA R M
CYC 1
PI US 5077284 A 19911231 (199204)*
ADT US 5077284 A US 1988-291969 19881230
PRAI US 1988-291969 19881230
IC A01N045-00; **A61K009-08**; A61K031-56

AB US 5077284 A UPAB: 19970806
A method for increasing a host mammalian immune system's response to infectious agents and immunogens comprises the subcutaneous, transdermal, intradermal, oral or nasal admins. of a prophylactic or therapeutic amt. of **dehydroepiandrosterone** (**DHEA**) to up-regulate the host immune system against infection and immunogen. The up-regulation results in a greater host resistance against infection and aids the host immune system's response when exposed to the immunogen.
USE/ADVANTAGE - The method is esp. useful for increasing a host mammal's immune system to viral infection e.g. coxsackievirus B4, HSV-2 and HIV (both AIDS and ARC) and also to prevent infection in e.g. surgery patients, burn victims, cancer patients receiving chemotherapy, hypoplastic or aplastic anaemias, or diabetics. Up-regulation of immunity may also be used in common dormitories, veterinary medicine and in animal populations during stressful shipping, mixing and early life adaptation. **DHEA** increases the number of antibody-producing cells and white blood cells associated with viral resistance and markedly reduces virus-induced mortality. Dosage is 25mg-2mg/kg body weight, pref. administered subcutaneously or orally. Infection of human coxsackievirus B4 strain (100,000 pfu/animal) causes 90% mortality, reduced to 37% when animals were treated with **DHEA**. @(12pp Dwg.No.0/4)
FS CPI
FA AB; DCN
MC CPI: B01-D02; B12-A01; B12-A02C; B12-A06; B12-A07; B12-B04; C01-D02; C12-A01; C12-A02C; C12-A06; C12-A07; C12-B04; D05-H

L96 ANSWER 24 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1991-317959 [43] WPIDS
DNC C1991-137436
TI New inclusion complexes of lipophilic cpd. - and hydroxypropyl-cyclodextrin, with improved solubility in water, esp. for steroid and peptide pharmaceuticals.
DC B04
IN IRIE, T; PITHA, J; TORRES, LABANDEIRA J J; TORRES-LABANDEIRA, J J; TORRESLABA, J J
PA (USDC) US DEPT OF COMMERCE; (USSH) US DEPT HEALTH & HUMAN SERVICES; (USSH) NAT INST OF HEALTH; (USDC) US SEC OF COMMERCE
CYC 17
PI US 7585792 A 19910917 (199143)*
WO 9204888 A 19920402 (199216) EN 26p
RW: AT BE CH DE DK ES FR GB GR IT LU NL SE
W: AU CA JP
US 5120720 A 19920609 (199226) 6p A61K009-18 <--
AU 9187268 A 19920415 (199230) A61K009-18 <--
ADT US 7585792 A US 1990-585792 19900920; WO 9204888 A WO 1991-US6704 19910919; US 5120720 A US 1990-585792 19900920; AU 9187268 A AU 1991-87268 19910919, WO 1991-US6704 19910919
FDT AU 9187268 A Based on WO 9204888
PRAI US 1990-585792 19900920
REP US 4727064; US 4877774; US 4877778; US 5024997; WO 8502767
IC ICM **A61K009-18**
ICS A61K000-01; C08B037-16
AB US 7585792 A UPAB: 19930928
Inclusion complexes (A) of lipophilic cpds. (I) and hydroxypropylcyclodextrin (II) are new. Pref. (A) are made by dissolving (I) and (II) in an aq. soln. contg. a volatile co-solvent, then evapn. or lyophiisation of the soln. In prepn. of (A), the co-solvent is at 2-95%, and is esp. NH4OH or EtOH. The lyophilised complex is amorphous and pref. for **tabletting** by direct compression.
USE/ADVANTAGE - (A) have greater water solubility than (I), and can be prepd. relatively simply on a large scale. They (and their aq. solns) are physically stable and can be used as pharmaceuticals, esp. where (I) are steroids or peptides. (A) can be formulated as solns. for injection or for oral admin.
0/0
FS CPI

FA AB; DCN
MC CPI: B01-C05; B01-D02; B02-A; B02-G; B04-C02B1
ABEQ US 5120720 A UPAB: 19930928
A new amorphous hydroxypropylcyclodextrin : lipophile complex is prepd. by dissolving the components in an aq. soln. comprising a volatile cosolvent, and evapn. or lyophilisation to dryness. The cyclodextrin may be alpha, beta or gamma. Pref. the cosolvent is 70-95% aq. ethanol or 2-20% NH4OH. The lipophile may be a steroid e.g. 5-androstene-3-beta, 17 beta-diol, 4-androstene- 3,17-dione, etc., or a macrocylic antibiotic e.g. amphotericin B, or vitamins D or E.
USE - The inclusion complexes are amorphous and stable and the method is suitable for large scale use.
0/0

L96 ANSWER 25 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1991-287943 [39] WPIDS
DNN N1991-220365 DNC C1991-124574
TI Bi laminate with muco-adhesive face for controlled agent release - contg. fumed silica for enhanced muco-adhesive properties.
DC A96 B07 D22 P32
IN LEUNG, S H S; SANVORDEKE, D R
PA (WATS-N) WATSON LABS INC
CYC 1
PI US 5047244 A 19910910 (199139)*
ADT US 5047244 A US 1988-202662 19880603
PRAI US 1988-202662 19880603
IC A61F013-00; **A61K009-26**
AB US 5047244 A UPAB: 19930928
A therapeutic dosage form comprises: (a) an anhydrous but hydratable monolithic polymer matrix, contg. amorphous fumed silica and a therapeutic agent, and defines a mucoadhesive face; and (b) a water insol. barrier layer, secured to the polymer matrix, and defining a non-adhesive face. The therapeutic agent and polymer are respectively, either; (i) dehydroandrosterone and polyethylene glycol (PEG) of average M.wt. about 4000, in a wt. ratio about 1:4; or (ii) nifedipine and PEG of average M.wt.
8000, in a wt. ratio 1:2; or (iii) piroxicam and PEG of average m.wt. 8000, in a wt. ratio 1:2; or (iv) albuterol and PEG of average M.wt. 8000, in a wt. ratio 1:2; or (v) **dehydroepiandrosterone** and PEG of average M.wt. 8000, in a wt. ratio 1:2; or (vi) phenylpropanolamine and PEG of average M.wt. 8000, in a wt. ratio 1:2; or (vii) 17-beta-oestradiol and PEG of average M.wt. 8000, in a wt. ratio 1:2.
USE/ADVANTAGE - The mucoadhesive device is well suited for the systemic delivery of therapeutic agents via mucosal, i.e. buccal, vaginal and rectal, routes. Agents showing absorption problems by the gastrointestinal route due to solubility limitations, pH or enzymatic degradation and/or extensive metabolism by the liver, are partic. suitable. @(15pp Dwg.No.3/5)@
FS CPI GMPI
FA AB; GI; DCN
MC CPI: A05-H03; A12-V01; B01-A02; B01-D02; B04-C03C; B06-F02; B10-B01A; D09-C04B

L96 ANSWER 26 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1991-163933 [22] WPIDS
DNC C1991-070919
TI Adhesive carriers for trans-mucosal drug deliver - comprising hydratable acrylic acid polymer or sugar alcohol polyethylene glycol matrix and fumed silica.
DC A25 A96 B07
IN LEUNG, S S; SANVORDEKER, D R; LEUNG, S H S; SANVORDEKE, D R
PA (WATS-N) WATSON LAB INC
CYC 16
PI WO 9106289 A 19910516 (199122)*
RW: AT BE CH DE FR GB IT LU NL SE
W: AU DK FI JP NO

AU 8945286 A 19910531 (199135)
FI 9103127 A 19910627 (199137)
EP 452334 A 19911023 (199143)
R: AT BE CH DE FR GB IT LI LU NL SE
DK 9101276 A 19910628 (199144)
NO 9102558 A 19910628 (199144)
JP 04502913 W 19920528 (199228) 16p A61K009-00 <--
AU 640114 B 19930819 (199340)# A61K009-20 <--
EP 452334 A4 19911211 (199520)

ADT EP 452334 A EP 1989-912797 19891031; JP 04502913 W WO 1989-US4882 19891031, JP 1990-500642 19891031; AU 640114 B AU 1989-45286 19891031; EP 452334 A4 EP 1989-912797

FDT JP 04502913 W Based on WO 9106289; AU 640114 B Previous Publ. AU 8945286, Based on WO 9106289

PRAI WO 1989-US4882 19891031; NO 1991-2558 19910628

REP US 4740365; EP 108218; EP 306454

IC **A61K009-20**; **A61K009-70**; A61K047-04; A61K047-26; A61K047-34
ICM **A61K009-20**
ICS **A61K009-70**; A61K031-135; A61K031-455; A61K031-54; A61K031-565; A61K047-04; A61K047-26; A61K047-34

AB WO 9106289 A UPAB: 19930928
Adhesive carriers for therapeutic agents comprise a hydratable anhydrous polymer or sugar alcohol matrix contg. sufficient amorphous fumed silica to improve the adhesion of the matrix to mucous membranes. Pref. the matrix material is a polyethylene glycol (PEG) with a mol.wt. of 1500-8500 (4000-8000), an acrylic acid polymer, or mannitol. Polymer matrices may also contain a hydratable adjuvant and/or a water-swellable, water-insol., fibrous, crosslinked, carboxy-functional polymer, e.g. `Carbophil' (RTM). Specified drugs for inclusion in the PEG-based carriers are nifedipine, oestradiol, piroxicam, albuterol, dehydro-epinoradrosterone and phenylpropanolamine.
USE - Dosage forms comprising a drug-contg. adhesive carrier as above and a water-insol. barrier layer are useful for buccal, vaginal or rectal admin. of the drug.
0/5

FS CPI

FA AB; DCN

MC CPI: A12-V01; B01-A02; B01-D02; B04-C03B; B04-C03C; B05-B02C; B06-F02; B07-D04C; B10-A07; B10-B03B

L96 ANSWER 27 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

AN 1991-157617 [22] WPIDS

DNC C1991-068024

TI Enhanced bio-availability adsorbate formulation - contg. steroid and polyvinyl pyrrolidone adsorbed on crosslinked polyvinyl pyrrolidone.

DC A96 B01 B07

IN BOURKE, E A; MULLIGAN, S

PA (ELAN-N) ELAN CORP PLC

CYC 15

PI EP 429187 A 19910529 (199122)*
R: AT BE CH DE ES FR GB GR IT LU NL SE
JP 03275634 A 19911206 (199204)
EP 429187 B1 19940105 (199402) EN 19p A61K009-18 <--
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DE 69005797 E 19940217 (199408) A61K009-18 <--

ADT EP 429187 A EP 1990-311738 19901025; JP 03275634 A JP 1990-288251 19901025; EP 429187 B1 EP 1990-311738 19901025; DE 69005797 E DE 1990-605797 19901025, EP 1990-311738 19901025

FDT DE 69005797 E Based on EP 429187

PRAI IE 1989-3448 19891026

REP EP 163178; EP 232155; EP 274176; GB 2153677

IC **A61K009-18**; A61K031-56; A61K047-32
ICM **A61K009-18**
ICS A61K031-56; A61K031-565; A61K047-32

AB EP 429187 A UPAB: 19930928

Pharmaceutical compsn. comprises mixt. of 1 pt. wt. of steroid cpd. of formula (I) and 0.1-10 pts. wt. of polyvinylpyrrolidone, adsorbed on crosslinked polyvinylpyrrolidone in ratio of 1 pt. wt. of mixt. to 0.20-20 pts. wt. of crosslinked polyvinylpyrrolidone.

In (I), R is H or Br; R1 is H, SO2OM (M is H or Na), -SO2O-OCH2-C(OCOR2)HCH2OCOR3.

(Where R2 and R3 are each 1-14C alkyl), gp. (i) or gp. (ii).

Pref. there are present 0.1-2 pts. of polyvinylpyrrolidone for each 1 pt. of (I) and 1 pt. of mixt. for 0.2-10 pts. of crosslinked polyvinylpyrrolidone. Suitably the polyvinylpyrrolidone has average molecular wt. of 65,000-250,000.

Compsn. may be, e.g., in form of powder, granule, **tablet**, capsule or suspension, and may be blended with polymeric or mineral material that disintegrates in presence of water, e.g., natural starch, pregelatinised starch, modified corn starch, Na starch glycolate, Na carboxymethylcellulose, carboxymethylcellulose, cellulose, etc..

USE/ADVANTAGE - Compsn. enhances bioavailability of steroid by improving its absorption. Used e.g., in instances of adrenal insufficiency. Specified steroids (I) are **dehydroepiandrosterone**, 16-bromoepiandrosterone and their hydrates, polymorphs and enantiomers, and isomers and salts of these cpds..

0/0

FS CPI
FA AB; DCN
MC CPI: A04-D05; A12-V01; B01-D02; B04-C03B; B12-G04B
ABEQ EP 429187 B UPAB: 19940223

An enhanced bioavailability adsorbate formulation comprising an adsorbate of a mixture of one part by weight of a compound of the general formula (I) in which R is a hydrogen or bromine atom, and R1 is a hydrogen atom, an SO2OM group wherein M is a hydrogen or sodium atom, a sulphatide group (II), wherein each of R2 and R3, which may be the same or different, is a straight or branched chain alkyl radical of 1 to 14 carbon atoms, a phosphatide group (III) wherein each of R2 and R3, which may be the same or different, is a straight or branched chain alkyl radical of 1 to 14 carbon atoms, or a glucuronide group (IV), and wherein the broken line represents an optical double bond, and the hydrogen atom at position 5 is present in the alpha- or beta-configuration or a mixture of both configurations, and from 0.1 to 10 parts by weight of polyvinylpyrrolidone, adsorbed on a cross-linked polyvinylpyrrolidone in a ratio of 1 part by weight of said mixture to 0.20 to 20 parts by weight of cross-linked polyvinylpyrrolidone.

Dwg. 0/2

L96 ANSWER 28 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1990-232865 [31] WPIDS
DNC C1990-100520
TI Vaginal suppository - comprises acceptable salt of **dehydro epi androsterone** sulphate and amino acid and hard fat having hydroxy valve of not more than 50.
DC B01 B07
IN AWATA, N; KAWASHIMA, T; NAKAGAWA, H; SAKAGUCHI, M
PA (KANE) KANEBO LTD
CYC 5

PI						
	EP 380036	A	19900801 (199031)*			
	JP 02193925	A	19900731 (199036)			
	PT 92940	A	19900731 (199041)			
	US 5246704	A	19930921 (199339)		5p	A61K031-56
	EP 380036	B1	19940112 (199403)	EN	10p	A61K031-565
	DE 69005834	E	19940224 (199409)			A61K031-565
	ES 2062117	T3	19941216 (199505)			A61K031-565
	JP 2546808	B2	19961023 (199647)		4p	A61K031-565

ADT EP 380036 A EP 1990-101245 19900122; JP 02193925 A JP 1989-14528 19890123; US 5246704 A Cont of US 1990-468309 19900122, US 1992-913102 19920714; EP 380036 B1 EP 1990-101245 19900122; DE 69005834 E DE 1990-605834 19900122, EP 1990-101245 19900122; ES 2062117 T3 EP 1990-101245 19900122; JP 2546808 B2 JP 1989-14528 19890123

FDT DE 69005834 E Based on EP 380036; ES 2062117 T3 Based on EP 380036; JP 2546808 B2 Previous Publ. JP 02193925
PRAI JP 1989-14528 19890123
REP A3...9049; EP 264524; FR 2322605; NoSR.Pub
IC **A61K009-02**; A61K031-56
ICM A61K031-56; A61K031-565
ICS **A61K009-02**; A61K047-18
AB EP 380036 A UPAB: 19930928
A vaginal suppository comprises a pharmaceutically acceptable salt of **dehydroepiandrosterone** sulphate, and, based on the wt. of the salt 0.2 to 0.3 parts by wt. of an amino acid and 1-20 parts by wt. of a hard fat having a hydroxy value of not more than 50. Also claimed is use of salt of **dehydroepiandrosterone** sulphate for preparing vginal suppository.
USE/ADVANTAGE - The suppository promotes maturation of the uterine cervix during late pregnancy to enhance the responsiveness of the uterine muscle to oxytocin. The suppository featuers an improved absorption of the active drug from the vagina as well as a good shelf life. The suppository contains 100-1500 mg of active component as a unit dosage.
0/0
FS CPI
FA AB; DCN
MC CPI: B01-D02; B04-B01B; B10-B02J; B12-M08
ABEQ US 5246704 A UPAB: 19931123
Vaginal suppository comprises a salt of **dehydroepiandrosterone** sulphate(I) and (based on wt. of (I)) 0.2-3 pts. amino acid and 1-20 pts. hard fat having a hydroxy value not more than 50. The amino acid is pref. Ala, Arg, Asp, aspartic acid, Cystine, Glu, glutamic acid, Gly, His, hydroxylysine, cysteine hydroxyproline, Leu, Ile, Lys, Met, Orn, phenylalanine, Pro, Ser, threonine, Trp, Tyr, Val etc..
USE/ADVANTAGE - The suppository gives improved absorption of the active drug from the vagina plus a good shelf life. (I) increases cervical ripeness at the terminal stage of pregnancy and potentiate the sensitivity to oxytocin of the uterine muscles.
Dwg.0/0
ABEQ EP 380036 B UPAB: 19940303
A vaginal suppository comprising a pharmaceutically acceptable salt of **dehydroepiandrosterone** sulfate, an amino acid and a hard fat having a hydroxy value of not more than 50, wherein said amino acid and said hard fat are present, based on the weight of said salt of **dehydroepiandrosterone** sulfate, in an amount of 0.2 to 3 parts by weight and 1 to 20 parts by weight, respectively.
Dwg.0/0

L96 ANSWER 29 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1988-362413 [51] WPIDS
DNC C1988-160309
TI Liq. suspension of drug contg. polymer particles in oil - used for oral admin. to given sustained release of medication.
DC A96 B07 P32
IN MULLIGAN, S
PA (ELAN-N) ELAN CORP PLC
CYC 17
PI EP 295941 A 19881221 (198851)* EN 22p
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
JP 01016717 A 19890120 (198909)
DK 8803336 A 19881220 (198910)
US 5156842 A 19921020 (199245) 12p A61K035-78
EP 295941 B1 19930317 (199311) EN 19p A61K009-10 <--
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
CA 1314215 C 19930309 (199315) A61K009-10 <--
DE 3879286 G 19930422 (199317) A61K009-10 <--
ES 2054807 T3 19940816 (199434) A61K009-10 <--
ADT EP 295941 A EP 1988-305556 19880617; JP 01016717 A JP 1988-149921 19880617; US 5156842 A Cont of US 1988-208401 19880617, Cont of US 1991-649225 19910128, US 1991-769160 19910927; EP 295941 B1 EP 1988-305556

19880617; CA 1314215 C CA 1988-569795 19880617; DE 3879286 G DE 1988-3879286 19880617, EP 1988-305556 19880617; ES 2054807 T3 EP 1988-305556 19880617

FDT DE 3879286 G Based on EP 295941; ES 2054807 T3 Based on EP 295941

PRAI IE 1987-1645 19870619

REP A3...8911; DE 3309763; GB 2166651; No-SR.Pub; US 3996355

IC ICM **A61K009-10**; A61K035-78
ICS A61F009-02; **A61K009-26**; **A61K009-48**

AB EP 295941 A UPAB: 19930923
Liquid suspension for oral administration consists of a suspension of non-toxic polymer particles carrying an active ingredient in a non-aqueous carrier. The particles have an average size of 0.1 to 150 microns. The active ingredient can be distributed on or through the polymer particles.

The non-aq. carrier is almond oil, araclus oil, castor oil, fractionated coconut oil, cotton seed oil, ethyl oleate oil, evening primrose oil, maize oil, olive oil, persic oil, poppy seed oil, safflower oil, sesame oil, soya oil, sunflower oil, sucrose polyester, paraffin oil, or silicone oil. Active ingredient is erythromycin ethyl succinate, toxithromycin, amoxicillin trihydrate, peptide, polypeptide, **dehydroepiandrosterone**, prednisolone, KCl, guaiphenesin or dextromethorphan.

USE - The compsn. has a sustained release effect. Any adverse taste is masked.

0/5

FS CPI GMPI

FA AB; DCN

MC CPI: A12-V01; B01-B02; B01-D02; B02-E; B02-P02; B02-T; B04-A04; B04-B01C1; B04-C01; B04-C03D; B05-A01A; B06-D18; B07-A02; B10-E04B; B10-G02; B12-M10A

ABEQ EP 295941 B UPAB: 19930923
A liquid antibiotic suspension for oral administration having improved bioavailability, comprising an antiobiotic suspended in an edible, oily vehicle, wherein the antibiotic is in the form of controlled release microparticles containing the antibiotic and optionally an excipient, the antibiotic of said microparticles being coated with, distributed through or absorbed onto at least one non-toxic polymer, and said microparticles further having an average size in the range of 0.1 to 150 micron and a controlled release of antibiotic which in combination with the oily vehicle permits controlled absorption of antibiotic effective to improve the bioavailability of said antibiotic over that obtained in aqueous liquid suspensions.

0/4

ABEQ US 5156842 A UPAB: 19930923
Non-aq. pharmaceutical liq. suspensions with improved bioavailability and for oral administration comprise an antibiotic (I) suspended in an edible non-aq. carrier (II). (I) is in the form of controlled release microparticles which opt. contain an excipient.

(I) is coated with, distributed through or absorbed on to a non-toxic polymer. The microparticles have an average size of 0.1-150 microns and a rate of release which gives improved bioavailability over that obtd. with aq. suspensions. The carrier is pref. an animal, vegetable or mineral oil, esp. fractionated coconut oil, soya oil, sunflower oil, paraffin oil or silicone oil.

USE - (claimed). Esp. for administration of erythromycin ethyl succinate, roxithromycin or amoxicillin trihydrate.

1/5

L96 ANSWER 30 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

AN 1988-113801 [17] WPIDS

DNC C1988-050932

TI **Dehydro epi androsterone** sulphate salt in vaginal suppository - also contg. a hard fat, for accelerating maturation of uterine cervix in pregnant women.

DC B01

IN SUGIMOTO, I; TSUTA, H

PA (KANE) KANEBO LTD

CYC 20
PI EP 264524 A 19880427 (198817)* EN 8p
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
JP 63104924 A 19880510 (198824)
US 4789669 A 19881206 (198851) 5p
PT 84515 A 19881130 (198905)
CN 87102641 A 19880504 (198924)
EP 264524 B 19910605 (199123)
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
DE 3770571 G 19910711 (199129)
KR 9005822 B 19900813 (199142)
ES 2022181 B 19911201 (199202)
JP 05017884 B 19930310 (199313) 5p A61K031-565
CN 1025591 C 19940810 (199536) A61K009-02 <--
ADT EP 264524 A EP 1987-103351 19870309; JP 63104924 A JP 1986-250157 19861020; US 4789669 A US 1987-24204 19870310; JP 05017884 B JP 1986-250157 19861020; CN 1025591 C CN 1987-102641 19870409
FDT JP 05017884 B Based on JP 63104924
PRAI JP 1986-250157 19861020
REP DD 67547; US 4005200; US 4061744; US 4496556
IC ICM A61K031-565
ICS **A61K009-02**; A61K031-56; A61K047-44
AB EP 264524 A UPAB: 19930923
A vaginal suppository comprises a salt of **dehydroepiandrosterone** sulphate (DHAS) and a hard fat with a hydroxyl value not above 50.
USE/ADVANTAGE - The suppository is useful for improving the antepartum condition of pregnant women. It may be administered by the intravaginal route, which is relatively expedient, and it has a long shelf life.
0/0
FS CPI
FA AB; DCN
MC CPI: B01-D02; B04-B01B; B12-G04D; B12-M08
ABEQ EP 264524 B UPAB: 19930923
A storage stable vaginal suppository comprising a pharmaceutically acceptable salt of dehydroeplandrosterone sulphate (DHAS-salt) in admixture with a hydrophobic base consisting essentially of 1 to 20 parts by weight of a hard fat to each part by weight of the DHAS-salt, said fat having a hydroxyl value not exceeding 50.
ABEQ US 4789669 A UPAB: 19930923
New storage-stable vaginal suppository comprises 1-20 pts.wt. salt of dehydroepiandrostane sulfate ad mit. with hydrophobic base consisting of hard fat with hydroxyl value not above 50 (2.3-46). Pref. wt. ratio is 1:4 to 1:9. Pref. salt is sodium dihydrate crystals of diam. 3-20 micron.
USE - to improve anti-partum condition of pregnant woment and enhance responsiveness of uterine smooth muscle to oxytocin. Dose: 100-1500 mg of DHAS salt 1-3/day at 37-39 th. week of gestation

L96 ANSWER 31 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1977-16438Y [10] WPIDS
TI Stable **dehydro-epiandrosterone** compsn. - prepd. by freeze drying solns. contg. a stabiliser.
DC B01
PA (KANE) KANEBO LTD
CYC 19
PI BE 845795 A 19770302 (197710)*
DE 2639849 A 19770317 (197712)
NL 7609833 A 19770308 (197712)
SE 7609443 A 19770328 (197715)
JP 52031821 A 19770310 (197716)
DK 7603965 A 19770502 (197721)
FR 2322605 A 19770506 (197723)
ZA 7605289 A 19770704 (197738)
US 4061744 A 19771206 (197750)
DD 127381 A 19770921 (197751)
NO 7700743 A 19780130 (197808)

JP 53007662 A 19780124 (197810)
FI 7701525 A 19780228 (197812)
PT 66228 A 19780125 (197812)
HU 15609 T 19781028 (197845)
CA 1047404 A 19790130 (197907)
IL 50376 A 19791031 (197948)
GB 1561360 A 19800220 (198008)
JP 55030769 B 19800813 (198036)
JP 57008086 B 19820215 (198210)
CS 7605741 A 19811130 (198215)
SU 1072789 A 19840207 (198439)
DE 2639849 C 19870212 (198706)
NL 183385 B 19880516 (198823)
PRAI JP 1975-108197 19750905; JP 1975-108917 19750905; JP 1976-80613 19760706
IC **A61K009-08**; A61K031-56; A61K047-00; C07J001-00
AB BE 845795 A UPAB: 19930901
Prepn. of stable dehydraepiandrosterone sulphate (I) compsns. for parenteral administration comprises freeze drying an aq. soln. of a water-soluble salt of (I) contg. a stabiliser comprising dextran, "macrogol", a neutral or basic amino acid, an alkali metal salt of a weak acid and/or a solid amine.

The soln. is pref. sterile filtered before freeze drying. The stabiliser is pref. present in an amt. of 10-200% of the wt. of the (I) salt. The latter is pref. an alkali metal salt. The prefd. stabilisers are glycine, arginine, Na tartrate, K hydrogen phosphate, alanine, tris(hydroxymethyl)aminomethane, dextran and macrogol.

(I) is used to promote safe, normal birth by increasing the sensitivity of uterine muscle to oxytocin. The compsns. have a long shelf life and can readily be dissolved in sterile H2O to prepare injection solns. In an example a mixt. of 100 mg of the Na salt of (I) and 200 mg macrogol 4000 (Japanese Pharmacopeia) was dissolved in 5 ml of sterile H2O and the soln. freeze dried in ampoules. The ampoules were kept at 50 degrees C for 20 days. The residual (I) content after this period was 96.0%.
FS CPI
FA AB
MC CPI: B01-D02; B04-C02; B04-C03C; B05-A01A; B05-A01B; B10-A17; B10-B02B; B10-B03B; B12-G04; B12-M06

L96 ANSWER 32 OF 32 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1976-48905X [26] WPIDS
TI **Dehydro-epiandrosterone** sulphate recrystallisation - from aq hydrophilic organic solvent, giving thermostable crystals soluble in water.
DC B01
PA (KANE) KANEBO LTD
CYC 1
PI JP 51054542 A 19760513 (197626)*
PRAI JP 1974-116297 19741009
IC C07J001-00
AB JP 51054542 A UPAB: 19930901
Water-soluble and thermostable 0.1-5 u scale-like crystals of **dehydroepiandrosterone** sulphate are obtd. by recyrstallisation from a hydrophilic organic solvent contg. 5 to 30% by vol. of water. The hydrophilic organic solvent may be ethanol, propanol, acetone, methylethylketone, dioxane, etc.
FS CPI
FA AB
MC CPI: B01-D02; **B12-M11**

=> d all abeq tech tot l99

L99 ANSWER 1 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1991-232420 [32] WPIDS

DNC C1991-101022
TI Use of 17-keto steroid derivs. - for preventing controlling and reversing hypertension, essential hypertension with minimal side effects.
DC B01
IN MASTERSON, J G
PA (ELAN-N) ELAN CORP
CYC 2
PI GB 2240472 A 19910807 (199132)*
ZA 9100614 A 19911030 (199149)
ADT GB 2240472 A GB 1991-1774 19910128; ZA 9100614 A ZA 1991-614 19910128
PRAI IE 1990-306 19900129
IC A61K031-56
AB GB 2240472 A UPAB: 19930928
The 17-ketosteroids have formula (I). In (I), R = H or Br; R1 = H, SO2OM, sulphatide, phosphatide or glucuronide; M = H or Na. The broken line = an opt. double bond. H atom at position 5 is in the (alpha) and/or (beta) configuration. The use of **dehydroepiandrosterone**, its hydrates, **polymorphs**, enantiomers, isomers and salts is specifically claimed. Hypertension is associated with low or sub-normal levels of **dehydroepiandrosterone**.
USE/ADVANTAGE - (I) has minimal toxicity and side effects and is administered orally or parenterally. Unit dose contains 1-1000 (5-500) mg of (I).
0/0
FS CPI
FA AB; DCN
MC CPI: B01-D02; B12-C06; B12-C10; B12-F02; B12-F05; B12-G02; B12-G04

L99 ANSWER 2 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1991-157617 [22] WPIDS
DNC C1991-068024
TI Enhanced bio-availability adsorbate formulation - contg. steroid and polyvinyl pyrrolidone adsorbed on crosslinked polyvinyl pyrrolidone.
DC A96 B01 B07
IN BOURKE, E A; MULLIGAN, S
PA (ELAN-N) ELAN CORP PLC
CYC 15
PI EP 429187 A 19910529 (199122)*
R: AT BE CH DE ES FR GB GR IT LU NL SE
JP 03275634 A 19911206 (199204)
EP 429187 B1 19940105 (199402) EN 19p A61K009-18
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DE 69005797 E 19940217 (199408) A61K009-18
ADT EP 429187 A EP 1990-311738 19901025; JP 03275634 A JP 1990-288251 19901025; EP 429187 B1 EP 1990-311738 19901025; DE 69005797 E DE 1990-605797 19901025, EP 1990-311738 19901025
FDT DE 69005797 E Based on EP 429187
PRAI IE 1989-3448 19891026
REP EP 163178; EP 232155; EP 274176; GB 2153677
IC A61K009-18; A61K031-56; A61K047-32
ICM A61K009-18
ICS A61K031-56; A61K031-565; A61K047-32
AB EP 429187 A UPAB: 19930928
Pharmaceutical compsn. comprises mixt. of 1 pt. wt. of steroid cpd. of formula (I) and 0.1-10 pts. wt. of polyvinylpyrrolidone, adsorbed on crosslinked polyvinylpyrrolidone in ratio of 1 pt. wt. of mixt. to 0.20-20 pts. wt. of crosslinked polyvinylpyrrolidone.
In (I), R is H or Br; R1 is H, SO2OM (M is H or Na), -SO2O-OCH2-C(OCOR2)HCH2OCOR3.
(Where R2 and R3 are each 1-14C alkyl), gp. (i) or gp. (ii).
Pref. there are present 0.1-2 pts. of polyvinylpyrrolidone for each 1 pt. of (I) and 1 pt. of mixt. for 0.2-10 pts. of crosslinked polyvinylpyrrolidone. Suitably the polyvinylpyrrolidone has average molecular wt. of 65,000-250,000.
Compsn. may be, e.g., in form of powder, granule, tablet, capsule or suspension, and may be blended with polymeric or mineral material that

disintegrates in presence of water, e.g., natural starch, pregelatinised starch, modified corn starch, Na starch glycolate, Na carboxymethylcellulose, carboxymethylcellulose, cellulose, etc..
USE/ADVANTAGE - Compsn. enhances bioavailability of steroid by improving its absorption. Used e.g., in instances of adrenal insufficiency. Specified steroids (I) are **dehydroepiandrosterone**, 16-bromoepiandrosterone and their hydrates, **polymorphs** and enantiomers, and isomers and salts of these cpds..
0/0

FS CPI
FA AB; DCN
MC CPI: A04-D05; A12-V01; B01-D02; B04-C03B; B12-G04B
ABEQ EP 429187 B UPAB: 19940223
An enhanced bioavailability adsorbate formulation comprising an adsorbate of a mixture of one part by weight of a compound of the general formula (I) in which R is a hydrogen or bromine atom, and R1 is a hydrogen atom, an SO2OM group wherein M is a hydrogen or sodium atom, a sulphatide group (II), wherein each of R2 and R3, which may be the same or different, is a straight or branched chain alkyl radical of 1 to 14 carbon atoms, a phosphatide group (III) wherein each of R2 and R3, which may be the same or different, is a straight or branched chain alkyl radical of 1 to 14 carbon atoms, or a glucuronide group (IV), and wherein the broken line represents an optical double bond, and the hydrogen atom at position 5 is present in the alpha- or beta-configuration or a mixture of both configurations, and from 0.1 to 10 parts by weight of polyvinylpyrrolidone, adsorbed on a cross-linked polyvinylpyrrolidone in a ratio of 1 part by weight of said mixture to 0.20 to 20 parts by weight of cross-linked polyvinylpyrrolidone.
Dwg. 0/2

=> fil drugl
FILE 'DRUGLAUNCH' ENTERED AT 16:50:48 ON 21 SEP 2000
COPYRIGHT (C) 2000 IMSWORLD Publications Ltd

FILE COVERS 1982 TO 29 Aug 2000 (20000829/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L105 ANSWER 1 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 1999:15370 DRUGLAUNCH
SO Drug Launches, (20 Dec 1999)
DN 0193492
CN Trade Name: **DHEA**
CO Manufacturer: Servimedic
CO Corporation: Servimedic

LNC Uruguay
LND Jun 1999
CC G3B Androgens
FS Product Listing
COMP Active Ingredient: **tabs** a: **prasterone**, 25 mg;
tabs b: **prasterone**, 50 mg.
NC 1
TX Reduces signs of aging, wrinkles
DOSFM **tabs**
LNP **tabs** a 20; **tabs** b 20

L105 ANSWER 2 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 1999:13092 DRUGLAUNCH
SO Drug Launches, (22 Nov 1999)
DN 0191173
CN Trade Name: **DHEA**
CO Manufacturer: Amni Advance Med.
CO Corporation: Amni Advance Med.
LNC Norway
LND Aug 1999
CC G3B Androgens
FS Product Listing
COMP Active Ingredient: **prasterone**, 25 mg.
NC 1
TX Helps aging, reduces appearance of wrinkles in skin
DOSFM **caps**
LNP caps 100 N Kr 115.50 (RPP)

L105 ANSWER 3 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 1999:2040 DRUGLAUNCH
SO Drug Launches, (22 Mar 1999)
DN 0180072
CN Trade Name: LEVOSPA KAYAKU
CO Manufacturer: Kayaku
CO Corporation: Kayaku
LNC Japan
LND Jan 1999
CC G3B Androgens
COMP Active Ingredient: **prasterone** sodium sulfate, 200 mg/vial.
NC 1
TX Menopausal disorders
DOSFM **vial dry**
LNP vial dry 10: Yen 12480 (NHI)

L105 ANSWER 4 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 1998:4005 DRUGLAUNCH
SO Drug Launches, (20 Apr 1998)
DN 0167050
CN Trade Name: **DHEA** SUPER HOMBRE
CO Manufacturer: Natural Balance
CO Corporation: Natural Balance
LNC Central America
LND Oct 1997
CC G3B Androgens
COMP Active Ingredient: **prasterone**, 25 mg, zinc, 10 mg.
NC 2
TX Male sexual dysfunction
DOSFM **caps**

L105 ANSWER 5 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 1998:3455 DRUGLAUNCH
SO Drug Launches, (20 Apr 1998)

DN 0166461
CN Trade Name: **DHEA**
CO Manufacturer: Natural
CO Corporation: Natural Health
LNC Dominican Republic
LND Sep 1997
CC G3B Androgens
COMP Active Ingredient: **prasterone**, 25 mg.
NC 1
TX Aging, reduces fine wrinkles
DOSFM **caps**

L105 ANSWER 6 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 1998:2627 DRUGLAUNCH
SO Drug Launches, (23 Mar 1998)
DN 0165632
CN Trade Name: GYNODIAN-DEPO
CO Manufacturer: Schering AG
CO Corporation: Schering AG
LNC Russia
LND 3Q 1997
CC G3E Androgen,Female Hormone Combinations
COMP Active Ingredient: estradiol valerate, **prasterone** enanate.
NC 2
TX Menopausal symptoms
DOSFM **amp parenteral**
LNP amp parenteral 1 ml: Rbl 53967 (RPP)

L105 ANSWER 7 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 97:3350 DRUGLAUNCH
SO Drug Launches, (24 Mar 1997)
DN 0152906
CN Trade Name: **DHEA**
CO Manufacturer: Breckenridge
CO Corporation: Breckenridge
LNC United States
LND Dec 1996
CC G3B Androgens
STA Unbranded
COMP Active Ingredient: **tabs**: **prasterone**, 25 mg; caps: **prasterone**, 25 mg; cream topical: **prasterone**, 1%.
NC 1
TX Helps aging, reduces appearance of fine wrinkles in skin
DOSFM **tabs; caps; cream topical**

L105 ANSWER 8 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 97:1761 DRUGLAUNCH
SO Drug Launches, (17 Feb 1997)
DN 0151299
CN Trade Name: GYNODIAN DEPOT
CO Manufacturer: Schering AG
CO Corporation: Schering AG
LNC Egypt
LND 3Q 1996
CC G3C Estrogens
COMP Active Ingredient: estradiol valerate, 4 mg, **prasterone** enanate, 200 mg.
NC 2
DOSFM **amp retard**
LNP amp retard 1 ml: EP 12.00 (RSP)

L105 ANSWER 9 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 97:93 DRUGLAUNCH
SO Drug Launches, (20 Jan 1997)
DN 0148405
CN Trade Name: GYNODIAN
CO Manufacturer: Schering AG
CO Corporation: Schering AG
LNC Latvia
LND 2Q 1996
CC G3C Estrogens
COMP Active Ingredient: estradiol valerate, **prasterone**.
NC 2
DOSFM **amp i m retard**
LNP amp i m retard 1 ml 1: Lat 4.42 (RPP)

L105 ANSWER 10 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 96:11702 DRUGLAUNCH
SO Drug Launches, (18 Nov 1996)
DN 0147938
CN Trade Name: LEVOSPA
CO Manufacturer: Isei
CO Corporation: Isei
LNC Japan
LND Aug 1996
CC G3B Androgens
COMP Active Ingredient: vial dry a: **prasterone** sodium sulfate, 100 mg; vial dry b: **prasterone** sodium sulfate, 200 mg.
NC 1
TX Facilitation of cervical ripening
DOSFM **vial dry**
LNP vial dry a 10: Yen 9380 (NHI); vial dry b 10: Yen 17330 (NHI)

L105 ANSWER 11 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 96:10487 DRUGLAUNCH
SO Drug Launches, (21 Oct 1996)
DN 0146710
CN Trade Name: AYLISTORMER
CO Manufacturer: Fuji Seiyaku Kogy
CO Corporation: Fuji Seiyaku Kogy
LNC Japan
LND Jul 1996
CC G3B Androgens
COMP Active Ingredient: vial dry a: **prasterone** sodium sulfate, 100 mg; vial dry b: **prasterone** sodium sulfate, 200 mg.
NC 1
TX Facilitation of ripening due to cervical ripening failure at the last stage of pregnancy (dilation failure of external os of uterus, cervical effacement failure and cervical softening failure).
DOSFM **vial dry**
LNP vial dry a 10: Yen 9380 (NHI); vial dry b 10: Yen 17330 (NHI)

L105 ANSWER 12 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 95:7373 DRUGLAUNCH
SO Drug Launches, (24 Jul 1995)
DN 0131343
CN Trade Name: GYNODIAN
CO Manufacturer: Schering AG
CO Corporation: Schering AG
LNC Slovak Republic
LND 1Q 1995
CC G3E Androgen,Female Hormone Combinations

COMP Active Ingredient: estradiol valerate, 4 mg, **prasterone** enanthate, 200 mg.
NC 2
DOSFM **amp i m retard**
LNP amp i m retard 1 ml 3: Kcs 784.90 (RSP)

L105 ANSWER 13 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 94:67160 DRUGLAUNCH
SO Drug Launches, (19 Sep 1994)
DN 0120777
CN Trade Name: DASTONIL GINSENG
CO Manufacturer: Montpellier
CO Corporation: Bago
LNC Argentina
LND Jul 1994
CC A13A Tonics
COMP Active Ingredient: ginseng extract, 200 mg, **prasterone** sodium sulfate, 10 mg, procaine hydrochloride, 50 mg, vitamin B12, 1000 mcg, vitamin B1, 50 mg, vitamin B6, 50 mg.
NC 6
TX Tonico y reconstituyente
DOSFM **tabs coated**
LNP **tabs** coated 30: P 29.70 (RSP)

L105 ANSWER 14 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 94:56442 DRUGLAUNCH
SO Drug Launches, (18 Oct 1993)
DN 0109724
CN Trade Name: GYNODIAN
CO Manufacturer: Schering AG
CO Corporation: Schering AG
LNC Czechoslovakia
LND Apr 1993
CC G3E Androgen,Female Hormone Combinations
COMP Active Ingredient: estradiol valerate, 4 mg/ml, **prasterone** enanthate, 200 mg/ml.
NC 2
DOSFM **amp i m retard**
LNP amp i m retard 1 ml 3: Kcs 721.40 (RSP)

L105 ANSWER 15 OF 15 DRUGLAUNCH COPYRIGHT 2000 IMSWORLD

AN 94:39544 DRUGLAUNCH
SO Drug Launches, (27 May 1991)
DN 1021546
CN Trade Name: MYLIS
CO Manufacturer: Hilton
CO Corporation: Hilton
LNC Pakistan
LND 4Q 1990
CC G3B Androgens
COMP Active Ingredient: **prasterone** sodium.
NC 1
DOSFM **vial**
LNP vial 100 mg PR 216.00 (RPP)

=> fil biosis
FILE 'BIOSIS' ENTERED AT 16:53:06 ON 21 SEP 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 20 September 2000 (20000920/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> d all tot

L111 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1998:158696 BIOSIS
DN PREV199800158696
TI Results of the GL701 (**DHEA**) multicenter steroid-sparing SLE study.
AU Petri, M. (1); Lahita, R.; McGuire, J.; Van Vollenhoven, R.; Strand, V.; Kunz, A.; Gorelick, K.; Chi, P. Y.; Hsu, H.; **Schwartz, K.**
CS (1) Johns Hopkins Med. Sch., Baltimore, MD USA
SO Arthritis & Rheumatism, (Sept., 1997) Vol. 40, No. 9 SUPPL., pp. S327.
Meeting Info.: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals Washington, DC, USA November 8-12, 1997 Association of Rheumatology Health Professionals
. ISSN: 0004-3591.
DT Conference
LA English
CC Pharmacology - General *22002
Bones, Joints, Fasciae, Connective and Adipose Tissue - General; Methods *18001
Immunology and Immunochemistry - General; Methods *34502
General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520
BC Hominidae 86215
IT Major Concepts
Pharmacology; Rheumatology (Human Medicine, Medical Sciences)
IT Diseases
SLE [systemic lupus erythematosus]: connective tissue disease, immune system disease
IT Chemicals & Biochemicals
GL701 [**DHEA**]: antiinflammatory - drug
IT Miscellaneous Descriptors
multicenter steroid-sparing study; Meeting Abstract
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae): patient
ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
RN **53-43-0 (DHEA)**

L111 ANSWER 2 OF 3 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1998:105709 BIOSIS
DN PREV199800105709
TI Pharmacodynamic modeling of **dehydroepiandrosterone** (**DHEA**), **DHEA**-SO4 and cortisol suppression by prednisolone.
AU Meno-Tetang, Guy M. L. (1); Blum, Robert A.; **Schwartz, Kenneth E.**; Jusko, William J. (1)
CS (1) Dep. Pharm., State Univ. New York, Buffalo, NY 14260 USA
SO Pharmaceutical Research (New York), (Nov., 1997) Vol. 14, No. 11 SUPPL., pp. S609.
Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Boston, Massachusetts, USA November 2-6, 1997 American Association of Pharmaceutical Scientists
. ISSN: 0724-8741.
DT Conference
LA English
CC Pharmacology - Drug Metabolism; Metabolic Stimulators *22003
Biochemical Studies - Sterols and Steroids *10067

Metabolism - Energy and Respiratory Metabolism *13003
Metabolism - Sterols and Steroids *13008
Endocrine System - Adrenals *17004
General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520
BC Hominidae 86215
IT Major Concepts
Metabolism; Pharmacology
IT Chemicals & Biochemicals
cortisol: suppression; **dehydroepiandrosterone** sulfate: pharmacodynamics modelling, suppression; **dehydroepiandrosterone** : pharmacodynamics modelling, suppression; prednisolone; prednisone
IT Miscellaneous Descriptors
pharmacokinetics; Meeting Abstract; Meeting Poster
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
RN 53-43-0 (**DEHYDROEPIANDROSTERONE**)
53-43-0 (DHEA)
50-23-7 (CORTISOL)
50-24-8 (PREDNISOLONE)
651-48-9 (**DEHYDROEPIANDROSTERONE** SULFATE)
53-03-2 (PREDNISONE)

L111 ANSWER 3 OF 3 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1998:105708 BIOSIS
DN PREV199800105708
TI Effects of oral GL701 (**dehydroepiandrosterone**) on single dose pharmacokinetics of oral prednisone and cortisol suppression in normal female volunteers.
AU Meno-Tetang, Guy M. L. (1); Blum, Robert A.; **Schwartz, Kenneth E.** ; Jusko, William J. (1)
CS (1) Dep. Pharm., State Univ. New York, Buffalo, NY 14209 USA
SO Pharmaceutical Research (New York), (Nov., 1997) Vol. 14, No. 11 SUPPL., pp. S608-S609.
Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Boston, Massachusetts, USA November 2-6, 1997 American Association of Pharmaceutical Scientists
. ISSN: 0724-8741.
DT Conference
LA English
CC Pharmacology - Drug Metabolism; Metabolic Stimulators *22003
Biochemical Studies - Sterols and Steroids *10067
Metabolism - Energy and Respiratory Metabolism *13003
Endocrine System - Adrenals *17004
General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520
BC Hominidae 86215
IT Major Concepts
Endocrine System (Chemical Coordination and Homeostasis); Metabolism; Pharmacology
IT Chemicals & Biochemicals
prednisolone: pharmacokinetics; prednisone: oral, pharmacokinetics, single dose; GL701 [**dehydroepiandrosterone**]
IT Miscellaneous Descriptors
cortisol suppression; pharmacodynamics; Meeting Abstract; Meeting Poster
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

```
RN   53-03-2 (PREDNISONE)
     50-23-7 (CORTISOL)
     53-43-0 (DEHYDROEPIANDROSTERONE)
     50-24-8 (PREDNISOLONE)


=> d his

     (FILE 'REGISTRY' ENTERED AT 15:50:24 ON 21 SEP 2000)
                DEL HIS
                ACT QAZI526/A
               ---------
L1   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  DHEA/CN
L2   (       532)SEA FILE=REGISTRY ABB=ON  PLU=ON  C19H28O2/MF AND C5-C6-C6-C6/E
L3   (        46)SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND 3 HYDROXY AND 17 ONE A
L4   (        10)SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT (LABELED OR ION OR (D
L5   (         8)SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND ANDROST
L6             8 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L1 OR L5)
               ---------
                ACT QAZI526A/A
               ---------
L7            15 SEA FILE=REGISTRY ABB=ON  PLU=ON  (149144-65-0/CRN OR 210700-55
               ---------

     FILE 'HCAPLUS' ENTERED AT 15:52:44 ON 21 SEP 2000
                ACT QAZI526B/A
               ---------
L8   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  DHEA/CN
L9   (       532)SEA FILE=REGISTRY ABB=ON  PLU=ON  C19H28O2/MF AND C5-C6-C6-C6/E
L10  (        46)SEA FILE=REGISTRY ABB=ON  PLU=ON  L9 AND 3 HYDROXY AND 17 ONE A
L11  (        10)SEA FILE=REGISTRY ABB=ON  PLU=ON  L10 NOT (LABELED OR ION OR (D
L12  (         8)SEA FILE=REGISTRY ABB=ON  PLU=ON  L11 AND ANDROST
L13  (         8)SEA FILE=REGISTRY ABB=ON  PLU=ON  (L8 OR L12)
L14  (        15)SEA FILE=REGISTRY ABB=ON  PLU=ON  (149144-65-0/CRN OR 210700-55
L15         7794 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 OR L14 OR DHEA OR DEHYDROE
               ---------
                E  PARASRAMPURIA J/AU
L16           34 S E3,E4
                E YONKER M/AU
                E SCHWARTZ K/AU
L17           88 S E3,E7,E19,E23
                E GURWITH M/AU
L18           15 S E3-E6
L19            1 S L15 AND L16-L18
L20          126 S L15 AND ?CRYS?
L21           22 S L15 AND POLYMORPH?
L22            0 S L15 AND POLY MORPH?
L23            4 S L20 AND L21
L24            1 S L23 AND POLYMORPH
L25            2 S L15 AND POLYMORPH
L26            2 S L24,L25
                SEL RN

     FILE 'REGISTRY' ENTERED AT 16:00:04 ON 21 SEP 2000
L27            7 S E1-E7
L28            4 S L27 AND L6,L7

     FILE 'HCAPLUS' ENTERED AT 16:01:40 ON 21 SEP 2000
L29            8 S L7
L30            7 S L29 NOT L26
L31            1 S L30 AND PHARMACEUT? (L) DOSAG? (L) FORM?/CW
L32            4 S L19,L26,L31
L33            0 S L20 AND EXCIPIENT
L34            3 S L15 AND EXCIPIENT
L35            1 S L34 NOT 64/SC,SX
L36            5 S L32,L35
```

```
L37         177 S L15 AND (CRYST? OR MOLECUL?)(L)STRUCTUR?/CW
L38         775 S (L6 OR L7)(L)(THU/RL OR BAC/RL OR PRP/RL)
L39          18 S L38 AND L20
L40          45 S L38 AND L37
L41          58 S L39,L40
L42          16 S L41 AND (1 OR 63 OR 17 OR 18)/SC,SX
L43           6 S (L6 OR L7)(L)FFD/RL
L44           6 S L43 AND L20,L37,L38
L45          64 S L44,L41 AND L15
L46          21 S L45 AND (1 OR 63 OR 17 OR 18)/SC,SX
L47           5 S L36,L44 AND L46
L48           4 S L21 AND FORM
L49           1 S L48 AND 63/SC
L50           6 S L47,L49
L51          21 S L21 NOT L46
L52          12 S L51 NOT 3/SC,SX
L53           1 S L52 AND CRYSTAL STRUCTURE
L54           1 S L52 AND IMMUNE RESPONSE
L55           8 S L50,L53,L54
L56          91 S L38 AND 63/SC,SX
L57          26 S L56 AND (DEHYDROEPIAN? OR DHEA)/TI
L58           4 S L57 AND (DEVICE OR AROMATASE OR INTERLEUKIN OR RETINOID)/TI
L59          22 S L57 NOT L58
L60          21 S L59 NOT CLATHRATE
L61          43 S L15 AND ?TABLET?
L62          61 S L15 AND ?CAPSUL?
L63          86 S L61,L62
L64           6 S L63 AND L20
L65           1 S L64 AND ANTIULCER
L66           9 S L55,L65
L67         181 S L15 AND (?GASTRO? OR ?GASTRI? OR ?INTESTIN? OR STOMACH OR DIG
L68           4 S L63 AND L67
L69           1 S L68 AND CONJUGATED/TI
L70          10 S L66,L69
L71          83 S L63 NOT L70
L72          24 S L71 AND 63/SC
L73          22 S L72 NOT L59
L74           5 S L73 AND (DYSTROPHY OR DELIVERY)/TI
L75           2 S L74 NOT (MUCOSAL OR COMPLEXES OR CYCLODEXTRIN)/TI
L76          12 S L70,L75
                SEL HIT RN

    FILE 'REGISTRY' ENTERED AT 16:35:09 ON 21 SEP 2000
L77           4 S E8-E11
L78          11 S L6,L77

    FILE 'REGISTRY' ENTERED AT 16:36:17 ON 21 SEP 2000

    FILE 'HCAPLUS' ENTERED AT 16:36:32 ON 21 SEP 2000

    FILE 'WPIDS' ENTERED AT 16:36:49 ON 21 SEP 2000
L79         230 S DHEA OR (DEHYDRO OR DE HYDRO)()(EPIANDROSTERONE OR EPI ANDROS
                E DEHYDROEPIANDROSTERONE/DCN
                E E3+ALL/DCN
L80         121 S E2 OR 0072/DRN
                E DEHYDROEPIANDROSTERONE/DCN
                E E4+ALL/DCN
L81          28 S E2
                E DEHYDROEPIANDROSTERONE/DCN
                E E5+ALL/DCN
L82          24 S E2
                E DEHYDROEPIANDROSTERONE/DCN
                E E6+ALL/DCN
L83          15 S E2
L84         270 S L79-L83
L85           4 SEA L84 AND (R031 OR R030 OR R032 OR R034 OR OR38)/M0,M1,M2,M3,
```

```
                M4,M5,M6
L86              6 S L84 AND (B12-M11? OR C12-M11?)/MC
L87             37 S L84 AND A61K009/IC,ICM,ICS,ICA,ICI
L88             40 S L85-L87
L89              7 S L88 AND ?TABLET?
L90              1 S L89 AND TRANS MUCOSAL
L91              7 S L89-L90
L92             33 S L88 NOT L91
L93             30 S L92 NOT EMULS?/TI
L94             27 S L93 NOT GREAS?/TI
L95             25 S L94 NOT FOLIN?/TI
L96             32 S L91,L95

     FILE 'WPIDS' ENTERED AT 16:47:07 ON 21 SEP 2000
L97              3 S POLYMOR? AND L84
L98              0 S POLY MOR? AND L84
L99              2 S L97 NOT ANTIGEN/TI
L100             1 S L99 NOT L96

     FILE 'DRUGLAUNCH' ENTERED AT 16:49:29 ON 21 SEP 2000
L101             5 S L79
L102            15 S PRASTERON? OR L101
L103             3 S L102 AND TAB?
L104            15 S L102 AND DOSFM/FA
L105            15 S L101-L104

     FILE 'DRUGLAUNCH' ENTERED AT 16:50:48 ON 21 SEP 2000

     FILE 'BIOSIS' ENTERED AT 16:51:03 ON 21 SEP 2000
L106          6459 S L15 OR L79 OR PRASTERON?
L107             0 S L106 AND (POLYMORPH OR POLY MORPH)
                 E PARASRAMPURIA J/AU
L108            23 S E3,E4
                 E YONKER M/AU
                 E SCHWARTZ K/AU
L109           324 S E3,E7,E22,E23,E25
                 E GURWITH M/AU
L110            79 S E3-E6
L111             3 S L106 AND L108-L110

     FILE 'BIOSIS' ENTERED AT 16:53:06 ON 21 SEP 2000
```